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ABSTRACT 
Over the past decade, Zika virus (ZIKV) has re-emerged as a pathogen of major health 
concern in the Western Hemisphere. Specifically, since 2007, 76 countries have announced 
new outbreaks of ZIKV, 29 of which also report increased incidence of CNS malformations 
such as microcephaly and also Guillain-Barre Syndrome [1]. These alarming statistics 
combined with the unique ability of ZIKV to be transmitted both sexually and in utero highlight 
the urgent need to study the mechanisms of ZIKV pathogenesis in order to ultimately develop 
vaccines, effective anti-viral therapies, and policies to control the spread of ZIKV disease. 
 
While ZIKV can be detected in human seminal fluid for months after the clearance of viremia, 
the cellular targets and mechanisms associated with persistent infection in the testes remains 
unclear. Mouse and NHP studies have recently shown that ZIKV can infect and damage the 
seminiferous tubules within the testes [2-5]. The seminiferous tubules are an immune 
privileged organ with a tight blood-testes barrier also known as the Sertoli-cell barrier (SCB), 
which protects developing spermatozoa from peripheral pathogens and environmental toxins. 
However, increased inflammatory mediators such as TNF-α and IL-1β,	matrix 
metalloproteinases, and cell-adhesion molecules (CAM) can disrupt the integrity of the SCB 
leading to pathologic outcomes [6, 7]. Therefore, the objective of this study was to 
characterize ZIKV replication kinetics and immune responses in primary human Sertoli cells 
(SC) and develop an in vitro SCB model to understand mechanisms of ZIKV transmigration 
across the barrier.  
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We demonstrate that primary human SC are highly susceptible to ZIKV as compared to the 
closely related dengue virus and induced expression of IFN-α, key cytokines and cell-
adhesion molecules (VCAM-1 and ICAM-1). Further, using an in vitro SCB model, we show 
that ZIKV was released on the adluminal side of the SCB model with higher efficiency when 
compared to the blood-brain barrier model. ZIKV-infected SC also exhibited enhanced 
adhesion of leukocytes that correlated with decrease in the SCB integrity. While ZIKV 
infection did not affect the expression of tight and adherens junction proteins such as ZO-1, 
claudin and JAM-A, exposure of SC to inflammatory mediators derived from ZIKV-infected 
macrophages led to the degradation of ZO-1 protein that correlated with increased SCB 
permeability. Collectively, our data suggest that infection of SC may be one of the crucial 
steps by which ZIKV gains access to the site of spermatozoa development and identifies SC 
as a therapeutic target. Finally, the SCB model opens up opportunities to assess interactions 
of SC with other testicular cells and lays the platform for future studies to test the ability of 
anti-ZIKV drugs to cross the barrier and clear testicular infection. 
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Chapter 1 
Zika virus and human disease  
	 2	
Discovery, history, and epidemiology of Zika virus: 
Zika virus (ZIKV) was first isolated from a sentinel Rhesus monkey in 1947 and 
subsequently in 1948 from a pool of A. africanus mosquitos found in the Zika forest of 
Uganda [8]. The first human case, however, was not described until 1954 from three 
patients in Nigeria [9]. Thereafter, serologic and entomologic surveys began to suggest a 
wide geographic distribution in the band of equatorial African countries (Sierra Leone, 
Gabon, Central African Republic, Senegal) and in parts of Asia (Pakistan, Malaysia, 
Indonesia) [10]. For over half a century, ZIKV was repeatedly isolated in many of these 
countries, however only 14 mild-febrile human infections were documented [11].  
 
The first large outbreak occurred in 2007 on Yap island in the Federated States of 
Micronesia, where an estimated 5,005 (72.6%) of the 6,892 residents were infected [12]. 
The next major outbreak happened in 2013 in French Polynesia, where an estimated 
30,000 (11.5%) of the 270,000 inhabitants were exposed [13]. As seen in Figure 1, during 
and after this time, ZIKV spread rapidly to other Pacific islands including New Caledonia, 
Cook Islands, Easter Island, Vanuatu, Soloman Islands, Samoa, and Fiji [14]. However, 
it wasn’t until ZIKV made landfall in Brazil in early 2015 that the virus truly emerged on 
the global stage where it caused between 440,000 to 1,300,000 infections by December 
2015 [15]. Futhermore, the association of ZIKV with more severe complications including 
Guillain-Barré syndrome (GBS) and severe fetal abnormalities such as microcephaly was 
a cause for serious alarm. 
 
Soon after, nearby countries in South America and the Caribbean began reporting 
autochthonous ZIKV circulation, attributed to the widespread distribution of Ae. aegypti 
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and Ae. albopictus in these regions [16]. Since then, 61 new countries worldwide have 
reported an outbreak of mosquito-borne Zika virus transmission, 29 of which have also 
reported increased incidence of microcephaly, other CNS malformations, and GBS 
potentially associated with ZIKV infection [1]. Currently in the U.S. and US territories there 
have been 5,285 and 36,583 symptomatic ZIKV disease cases reported, respectively 
[17]. 
 
Figure 1: Spread of ZIKV across the globe to date [14] 
 
Virology  
ZIKV belongs to the flavivirus genus of the Flaviviridae family, which includes other 
globally relevant arthropod-transmitted human pathogens such as dengue (DENV), West 
Nile (WNV), and Japanese encephalitis (JEV) viruses. Similar to these related viruses, 
ZIKV has an enveloped, spherical particle with an estimated diameter of ~50 nm. The 
viral genome is a single stand of linear, positive sense RNA roughly 10.8 kilo-bases in 
length. At the 5’ end is a type I cap structure (m7GpppAmG), which plays an important 
role in evasion of host restriction. Following the cap structure is a 5’ non-coding region 
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(NCR) that is required for modulating viral translation and RNA replication and is 
comprised of cis-acting RNA sequences and structures. Next is the open reading frame 
(ORF), which is translated into a polyprotein of 3,423 amino acids that is cleaved post 
translationally into three structural proteins (capsid, pre-membrane/membrane, and 
envelope) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and 
NS5), as shown in Figure 2 [18]. In general, the capsid (C) protein is involved with 
packaging of the viral genome. The pre-membrane (PrM) protein chaperones the folding 
and assembly of the envelope (E), which is the major protein involved in receptor binding 
and fusion [19, 20]. The non-structural proteins are responsible to form the viral replicase 
complex, which functions as a protease, helicase, methyltransferase, and RNA-
dependent RNA polymerase [21]. At the 3’ end of the genome, there is another NCR, 
which works together through long distance RNA-RNA interaction with the 5’ NCR and is 
also involved in counteracting the host cell’s response by serving as a substrate for host 
cell exoribonucleases to generate short non-coding sub-genomic flaviviral RNAs [10]. 
 
Figure 2. ZIKV genome and it’s encoded proteins [18] 
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A mature ZIKV particle consists of one copy of genomic RNA surrounded by multiple 
copies of the viral capsid protein, which form the nucleocapsid. This nucleocapsid is 
enclosed in a lipid bilayer derived from the modified membrane of the endoplasmic 
reticulum, with two surface proteins, membrane (M) and envelope (E) anchored through 
their two C-terminal transmembrane domains [11]. The M protein is a small proteolytic 
fragment of its precursor form prM, which acts as a transmembrane protein under the E-
protein shell of the mature virion. The smooth outer layer of the mature particle is 
constituted by 180 copies of the E protein, arranged as 90 antiparallel homodimers with 
an icosahedral symmetry [16] as depicted in Figure 3. 
 
Figure 3: Organization of a mature flavivirus particle [22] 
 
Phylogeny of ZIKV 
ZIKV is most closely related to the Spondweni virus, and these two viruses form the 
Spondweni serocomplex within the mosquito borne-clade of flaviviruses as shown in 
Figure 4. The next nearest relatives include the Illheus, Roico, and St. Louis encephalitis 
viruses [23]. ZIKV is also closely related to the four serotypes of DENV with approximately 
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43% amino acid identity across the viral polyprotein as well as the ectodomain of the 
envelope protein [24]. As described in the previous section (Discovery, History, and 
Epidemiology), it is assumed that the virus originated in East Africa and then spread to 
both West Africa and Asia about 50-100 years ago [25]. Following this historical pattern 
and based on the comparison of full and partial genome sequences of ZIKV, there are 
three distinct genotypes of Zika including the West African (eg. Nigerian and Senegal 
cluster), East African (eg. MR766 prototype cluster), and Asian (eg. Malaysian, Yap, and 
French Polynesian) strains. The Zika strain responsible for the current epidemic in Brazil 
and Central America is derived from the Asian lineage. 
 
Figure 4: Phylogenic tree of ZIKV African and Asian lineages [16] 
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It is estimated that the virus mutates about 10 bases a year or 0.01% of the genome [26]. 
Taking a closer look at the genomes between ZIKV strains, the percent identity of the 
ZIKV 2007 Yap strain with that of the prototype ZIKV MR 766 prototype strain isolated in 
1947 is 88.9% at the nucleic acid level (96.5% at the amino acid level) [16]. Interestingly, 
the 2007 Yap strain, the French Polynesian H/PF/2013 epidemic strain, and three strains 
of ZIKV from Senegal have a glycosylation motif at position 154 of the envelope, which is 
associated with an increase in virulence and is missing in the ZIKV MR 766 prototype 
strain [16]. Sequences from Brazil, Colombia, Puerto Rico, and Guatemala were all more 
than 99% identical with the French Polynesian strain (H/PF/2013), which provides further 
evidence that the virus was derived from Asia and the Pacific [16]. 
 
 
Lifecycle of ZIKV 
Like most other flaviviruses, ZIKV follows a general replication cycle that begins with 
virions attaching to the surface of target cells. Although the specific cell entry receptor 
utilized by ZIKV to bind and enter host cells is not well characterized, it has been reported 
that ZIKV enters via adhesion factors such as Heparin sulphate, C-type lectin receptors 
(ex. DC-SIGN), the low-density lipoprotein receptor, and diverse members of the 
phosphatidylserine receptor family (ex. AXL, Tyro3, and TIM-1) [27, 28].  
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Figure 5. The replication cycle of flaviviruses [28] 
 
Following receptor binding, ZIKV enters target cells via clatherin-mediated endocytosis 
and is transported to endosomes [10]. The low pH within the endosome induces a 
conformational change in the E glycoprotein that allows fusion of the virus with the 
endosomal membrane. Viral genomic RNA is then released form the virion into the 
cytoplasm and is translated into a single polypeptide at the endoplasmic reticulum (ER). 
The polyprotein is cleaved by host cellular signalase, furin, and viral serine protease 
(NS3) into the three structure and 7 non-structural (NS) viral proteins. These NS proteins 
form a replication complex inside the virus-induced ER-derived membranous 
compartments for the synthesis of complementary negative-sense RNA. This 
intermediate then serves as a template for production of additional (+)-sense genomic 
RNAs and further translation of viral proteins [10, 28] 
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Viral assembly takes place on the ER membrane and is facilitated by the prM and E 
proteins, which form a heterodimer and drive the budding of the viral genomic RNA and 
C proteins into the ER lumen to produce an immature non-infectious virion. These 
particles then must move through the cellular secretory pathway, during which furin and 
furin-like proteases cleave prM, generating the M structural protein. This processing leads 
to structural rearrangements of the M and E glycoproteins and generate mature virions 
that are then trafficked within vesicles to the cell surface where they are released by 
exocytosis [10, 28]. A general overview of ZIKV replication is shown in Figure 5. 
 
Mosquito and blood-borne transmission of ZIKV 
In Africa, ZIKV is maintained in an enzootic cycle between forest-dwelling species of 
Aedes mosquitos and nonhuman primates, however in urban and suburban 
environments, ZIKV is mainly transmitted in a human-mosquito-human cycle [29]. The 
Aedes genus of mosquito is specifically known to transmit ZIKV, however only a subset 
of species are competent vectors, (A. aegypti, A. albopictus, A. hensilli, and A. 
polynesiensis), with A. aegypti being the principal vector spreading the current outbreak 
in Latin America and the Caribbean. This is most likely because Ae. aegypti lives in close 
association to human habitats, feeds primarily on humans, and often bites multiple 
humans in a single blood meal [29]. There is currently no evidence that animals other 
than humans and non-human primates serve as amplifying hosts for ZIKV, suggesting a 
mode of transmission similar to dengue, Yellow Fever (YF), and Chikungunya viruses 
(CHIKV), but not like WNV that uses birds as amplification host  [24]. 
 
	 10	
Although the dose of ZIKV delivered by mosquitos is not available, previous studies with 
WNV and DENV help to speculate how much is required to cause infection. For example, 
in a mouse model it was demonstrated that WNV infected mosquitos inoculate 104-106 
PFU of virus extravascularly while probing [30]. Another study estimated that DENV 
transmitted by Ae. aegypti ranges from 104-105 PFU in a mosquito infectious dose [31]. 
Finally, experimental DENV challenges in human subjects have injected 103 of DENV-1 
and 105 DENV-3 subcutaneously to cause viremia and disease symptoms in humans [32]. 
Applying this data to ZIKV, it appears that the minimum dose to cause infection is between 
103-106 PFU, however the exact range remains to be determined.  
 
While A. aegypti and A. albopictus mosquitos are the main vectors responsible for ZIKV 
outbreaks, other modes of transmission have been reported, for example through blood 
transfusion in Brazil. Also during the French Polynesian outbreak in 2013, it was 
discovered that 2.8% of blood donors tested positive for Zika virus [33]. Although 
information about the possible risk of ZIKV infection via blood products is limited, Lustig 
et al detected ZIKV RNA in frozen whole blood samples up to two months after collection 
[34]. Fortunately, due to revised guidelines by the FDA to screen all donated blood 
samples for ZIKV, the U.S. has not reported any blood-transfusion related infections [33].  
 
Sexual transmission of ZIKV 
During acute infection, it has been documented that ZIKV can disseminate to the 
reproductive organs and be transmitted person to person through sexual intercourse. The 
first case of sexual transmission was reported in the United States in 2008 after a 36-
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year-old man, who had been preforming a mosquito sampling project in Senegal, returned 
home with ZIKV consistent symptoms. He and his wife reported having sexual intercourse 
in the days after he returned home and, within a week, his wife developed symptoms 
nearly identical to his own. Interestingly, the man also reported signs of hematospermia 
during this time-period. ZIKV was confirmed in both individuals by serologic testing. His 
wife had never traveled to Africa or Asia and had not left the US since 2007 [35]. The next 
affirmation came from a 44-year-old man in Tahiti who was infected with ZIKV during a 
large outbreak in 2013. This patient also noted hematospermia, which prompted blood, 
urine, and semen sample collection. Molecular diagnostics confirmed ZIKV RNA in the 
semen and urine at the level of 107 and 103 copies/ml respectively, two weeks after 
resolution of his symptoms, inoculation of the patient’s seminal fluid in Vero cells, 
produced replicative ZIKV particles, yet no viral replication was noted when cuturing a 
urine specimen [36]. Although hematospermia has been described in these initial 
patients, it is not a common symptom in ZIKV-infected men suggesting that sexual 
transmission is not the result of hematospermia- induced blood-borne transmission. 
Additional case reports from a recently published review by Grischott et al	are described 
in Figure 6 [37]. 
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Figure 6: Presence of ZIKV in seminal fluid and sexually transmitted cases [37] 
 
These case studies raise many interesting questions including the length of time that the 
virus can be detected in semen and in what fractions of seminal fluid can the virus be 
found. Currently, the longest documented persistence of ZIKV RNA in seminal fluid for 
181 days was described in a man in his early forties [38]. The shedding was sustained, 
persistent, and ranged from 103 and 104 copies/mL. ZIKV RNA was also detected in his 
plasma, urine, and saliva up to 9, 15, and 47 days after symptom onset, respectively [38]. 
Furthermore, ZIKV was found associated with the cellular component of his semen and 
remained undetectable in seminal plasma. While this patient may represent an extreme 
case, a recent cohort study with data from 150 acutely-infected human participants 
demonstrated that the median time until loss of ZIKV RNA in the serum is around 14 days 
compared to 34 days in seminal fluid (Figure 7) [39]. The prolonged detection of ZIKV 
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RNA in human seminal fluid, long after resolution of the virus in serum, strongly suggests 
that ZIKV has the ability to establish persistent testicular infection. 
Figure 7: Time until clearance of ZIKV RNA in serum, urine, and semen [39] 
 
Other questions that are important to the field are for how long can semen-positive males 
infect their partners? Do asymptomatic men also harbor virus in their seminal fluid? Can 
someone without symptoms sexually transmit the virus? In regard to the question of 
delayed sexual transmission, the longest documented case of sexual transmission is 44 
days after onset [40]. Two reports also suggests that ZIKV can be present in the semen 
and can be sexually transmitted in asymptomatic males [41, 42], however larger cohort 
studies are needed for stronger evidence. Other unexpected findings in regards to ZIKV 
sexual transmission includes male-to-male transmission through anal sex [43], presence 
of ZIKV RNA in the genital tract of females [44], and even a report of ZIKV transmission 
from a female to a male [45]. Of note, these reports are isolated case studies and further 
validation of these findings are required with larger cohort studies. 
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Currently, there have been 46 confirmed cases of sexual transmission reported in the 
United States [17]. Additionally, 12 other countries have reported cases of sexual 
transmission including Argentina, Canada, Chile, Peru, France, Germany, Italy, 
Netherlands, Portugal, Spain, New Zealand, the United Kingdom [1]. Although there is no 
convincing data currently available to determine the contribution of sexual vs. mosquito 
borne transmission in ZIKV endemic areas, mathematical modeling has determined that 
sexual transmission increases the risk of infection and epidemic size, prolongs current 
outbreaks, and broadens the geographic potential of ZIKV infection to Aedes non-
endemic regions [46]. Corroborating this model, recent data from Brazil demonstrates a 
higher incidence of ZIKV infection in women of reproductive age, suggesting the potential 
influence of sexual transmission [47].  
 
Although, ZIKV is currently the only known arbovirus linked to sexual transmission in 
humans [47], other related viruses have been detected in the male reproductive tract and 
seminal fluids. For example, in a patient who suffered terminal WNV encephalitis, viral 
antigens were detected in the prostate and testes [48]. Although not phylogenetically 
related, Ebola virus RNA has also been detected in semen as long as 7 to 9 months after 
disease onset and sexually transmitted cases have been confirmed [49, 50]. 
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Vertical Transmission of ZIKV 
Another new route of ZIKV transmission, which has never been described in any other 
flavivirus before, is the vertical transmission from mother-to-fetus during pregnancy. 
Substantial clinical and epidemiologic evidence now indicates that ZIKV can be passed 
to the developing child via this route. For example, ZIKV has been detected in amniotic 
fluid of mothers whose fetuses had cerebral abnormalities [29]. Viral antigen and RNA 
has also been identified in the brain tissue and placentas of children who were born with 
microcephaly and died soon after birth as well as in tissues from miscarriages [29]. 
Additionally, there have been cases of possible ZIKV transmission through breast milk in 
mothers who developed ZIKV symptoms just before giving birth, which has also been 
previously suggested for dengue, West Nile, and yellow fever [37, 51]. 
 
The first case of congenital ZIKV infection in the United States was actually reported here 
on Oahu in December 2015 [52]. The mother was specifically a 32 year-old woman from 
Brazil who at 7 weeks gestation was clinically diagnosed with a ZIKV infection. At 39 
weeks gestation, she delivered a male newborn that showed progessive neurologic 
deterioration in the first month of life [52]. Follow up studies examining archieved blood 
samples from mothers who gave birth to babies with microcephly in Hawaii between 2009 
and 2012 further determined that ZIKV positive cases and associated microcephly 
occurred in the United States as early as 2009 [53]. Selected studies with confirmed ZIKV 
infection and fetal outcomes from a recent review by Grischott et al. are described in 
Figure 8. 
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Figure 8: Confirmed mother-to-child ZIKV transmission [37] 
In 2016, the WHO reported that of 6,480 suspected cases of ZIKV-associated 
microcephaly in Brazil, 2,212 were investigated, and of which 39% (863) infants were 
confirmed to have microcephaly [54]. Furthermore, applying Shepards’s and Bradford Hill 
criteria to this phenomenon, vertical transmission of ZIKV satisfies the epidemiologic 
requirements to be identified as a teratogen [55]. Although many aspects of ZIKV 
transmission need further clarification, Figure 9 depicts a general overview. 
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Figure 9: Overview of ZIKV transmission cycles [56] 
 
Clinical symptoms of ZIKV disease 
It is estimated that only 20% of patients infected with ZIKV will become symptomatic with 
clinical manifestations [57]. In most adult cases, symptoms only last a few days to a week 
and include a low-grade fever, maculopapular pruritic rash, arthralgia, or non-purulent 
conjunctivitis. Other symptoms include headache, edema, myalgia gastrointestinal 
disorders, and lymphadenopathy [57]. Ninety-five percent of patients who do develop 
symptoms will do so by day 11 post infection [58]. Furthermore, the median time of viral 
persistence in serum is 10-14 days after infection, however this range can extend weeks 
further [39, 58].  
 
Laboratory tests are generally in the normal range, including blood cell and platelet counts 
as well as liver and kidney function tests [59]. However, leukopenia, mild 
thrombocytopenia, and increased transaminases have been described in some cases 
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[59]. There have also been some reports of mild hemorrhagic symptoms such as 
petechiae, minor mucosal bleeding, and hematospermia [59]. Generally, ZIKV is less 
neuroinvasive in adults than encephalitic flaviviruses such as WNV and Tick-borne-
encephalitis virus (TBEV) and fatality is rare excluding fetal losses among women infected 
during pregnancy and newborns with severe congenital ZIKV disease [60]. 
 
Complications of ZIKV infection 
More serious neurological effects associated with ZIKV infection in adults include Guillain-
Barré syndrome. GBS is a rare condition in which a person’s immune system attacks 
peripheral nerves that control muscle movement as well as transmit pain, temperature, 
and touch sensations. This can result in muscle weakness and loss of sensation in the 
legs and/or arms [61]. Symptoms typically last a few weeks and most individuals recover 
without long term neurological complications, however 3-5% of GBS patients are known 
to die from complications, which can include paralysis of the muscles that control 
breathing, lung clots, or cardiac arrest [61]. Specifically, in the French Polynesian 
outbreak, 38 cases of GBS occurred among an estimated 28,000 persons who sought 
medical care [29]. Since then, 22 other countries have reported ZIKV associated GBS 
cases [1].  
 
Vertical transmission of ZIKV is associated with several sequelae including congenital 
microcephaly, other neurologic disorders, and fetal loss. Microcephaly is defined as an 
occipitofrontal head circumference (OFC) below the third centile or more than two 
standard deviations (SD) below the mean for sex, age, and ethnicity [62]. This abnormality 
is associated with a reduction in brain volume and often intellectual and/or motor 
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disabilities [62]. The phenotype of microcephaly is variable and the spectrum of disorders 
is large. Microcephaly may be evident at birth (primary) or postnatally (secondary) when 
a child with a normal OFC drops to a value more than two SDs below the mean. Severe 
microcephaly is described as a child with an OFC below three SDs of the mean as shown 
in Figure 10 [62]. Typical findings of microcephaly via neuroimaging consist of 
calcifications, cortical disorders, and ventriculomegaly [63]. Other clinical manifestations 
include craniofacial disproportion, spasticity, seizures, and irritability. Brainstem 
dysfunctions, feeding difficulties, and ocular abnormalities have also been described [63].  
 
Microcephaly, however, is not a common condition. In the United States, birth defect 
tracking systems have estimated that microcephaly cases before ZIKV introduction 
ranged from 2-12 babies per 10,000 live births (0.02-0.12%) [64]. Furthermore, based on 
Hawaii Birth Defects Surveillance Report (1986–2005), there was a declining trend of 
incidence of microcephaly in Hawaii, with a rate of 13.6 per 10,000 total births in 1986 to 
4.8 per 10,000 total births in 2005. Over the period (1986–2005), a total of 370 cases of 
microcephaly were reported in Hawaii, which is equivalent to 9.4 per 10,000 total births 
[53]. However, based on the University of Hawaii Biorepository data, over the period of 
2007–2013, microcephaly rate was 14.7 per 10,000 total births. This increase in 
microcephaly rate coincides with ZIKV outbreaks in the Pacific starting in 2007 [53] 
 
Additional reports from the 2013-2014 French Polynesia outbreak suggest that the risk of 
microcephaly due to ZIKV infection in the first trimester of pregnancy was 0.95% [65] and 
modeling from the 2015-2016 outbreak in Brazil estimated the risk of microcephaly to be 
between 0.88-13% in the first trimester [66]. In the United States, a recent study showed 
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that in pregnancies with evidence of ZIKV infection, birth defects were reported in 5% of 
completed pregnancies [66]. This number is alarmingly higher than the risk of 
microcephaly pre-ZIKV era. Further, recent studies also suggest that the risk of 
microcephaly is highest if ZIKV exposure is in the first trimester of pregnancy [67].  
 
 
Figure 10: Infants with microcephaly as compared to a typical newborn [29] 
 
Pathogenesis of ZIKV 
ZIKV is primarily transmitted by the Aedes mosquito, which deposits the virus in the 
human epidermis and dermis while taking a blood meal. Once in the skin, the virus is 
thought to infect skin fibroblasts, epidermal keratinocytes, and dendritic cells (DC) based 
on in vitro studies [27]. Although it is yet to be shown with ZIKV, in vivo experiments using 
both WNV and DENV in mice have also demonstrated that skin Langerhans cells, 
macrophages, and infiltrating monocytes are also capable of sustaining productive 
infection of flaviviruses [68, 69]. Following peripheral inoculation, these skin antigen 
presenting cells (APC) subsequently migrate to the nearest draining lymph nodes, from 
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where the virus enters the bloodstream and establishes further sites of infection [68]. 
Human in vitro studies have also demonstrated that aortic, coronary artery, saphenous 
vein, and lymphatic endothelial cells are susceptible to infection, which could conceivably 
also facilitate hematogenous dissemination of the virus resulting in primary viremia [70].  
 
Figure 11: Schematic of the course of human and mosquito infection [14] 
 
As shown in Figure 11, the estimated median incubation period of ZIKV infection in 
humans is six days and ZIKV RNA is usually detectable in blood within the first 10 days 
after infection [59]  (Fig. 6). In the blood, peak viral load coincides with onset of symptoms 
(i.e. 5-7 days post infection) with titers typically ranging from 103-105 copies/ml, however 
high levels 107-109 copies/ml and prolonged viremia has been documented in some cases 
[59]. Non-human primate (NHP) studies have further validated the presence of viral RNA 
in peripheral tissue such as the spleen, kidney, bladder, joints, and peripheral nervous 
tissue [5, 71]. Interestingly, viral RNA was also found to be associated with the spinal 
cord, cerebrospinal fluid (CSF), and cerebellum [5, 71]. In the brain, ZIKV specifically 
infects neuronal cell types including neural progenitor cells, mature neurons, and 
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astrocytes [60]. Although there have been rare cases of ZIKV-associated 
meningoencephalitis in humans [72]  healthy adults rarely experience such sequelae and 
most neurologic complications are associated with birth defects in infants such as 
microcephaly.  
 
Several human studies now provide strong evidence of ZIKV RNA in both maternal and 
fetal tissues, including cord blood, several placental cell types (Hofbauer cells, 
trophoblasts, and endothelial cells), amniotic fluid, and the developing fetal brain [60]. 
ZIKV RNA has also been detected in the brain and placenta of spontaneously aborted 
human fetuses in the first and second trimesters [60]. Several studies now collectively 
suggest that ZIKV may have unique mechanisms to cross the placental barrier and cause 
fetal damage [59].  
 
Ocular abnormalities related to ZIKV have also been reported in infants, which closely 
resembles those caused by other RNA viruses such as CHIKV, DENV, and WNV [73]. 
Some of the ocular findings include macular problems such as pigment mottling and 
chorioretinal atrophy, in addition to optic nerve disorders for example hypoplasia [57]. 
Conjunctivitis is also a common symptom in infected adults [24]. These clinical 
manifestations are further corroborated with the discovery that ZIKV RNA and infectious 
virus can be recovered from human conjunctival fluids and tears [60]. Mouse studies have 
specifically demonstrated that the cornea, optic nerve, and neurosensory retina are 
susceptible to infection [60].  Furthermore, it has been proposed that ZIKV directly infects 
cells lining the blood-retinal-barrier (BRB), may establish a reservoir in the eye, and 
facilitate viral dissemination to other organs including the brain [73].   
	 23	
 
The female reproductive tract is also susceptible to ZIKV. In humans, viral RNA has been 
detected in urine and vaginal secretions [44] and in NHPs ZIKV has been found in the 
uterus and ovaries [5]. In vitro studies have further demonstrated that the vaginal 
epithelium and human uterine fibroblasts are susceptible to both African and Asian strains 
of ZIKV [60]. These in vitro and in vivo findings confirm the potential for sexual 
transmission and that uterine infection may contribute to impaired fetal development [60].  
 
Overall, there are two unique findings associated with ZIKV replication kinetics. First, 
ZIKV exhibits a broad tissue tropism and has the ability to access immune privileged sites, 
such as the placenta, brain, eye, and testes perhaps more readily than other flaviviruses, 
which may help to explain virus-induced congenital defects and spread through sex 
(Figure 12) [57]. Secondly, it has been noted that ZIKV preferentially infects and 
damages neural progenitor cells, which may explain its ability to impair development of 
the fetal brain, cause microcephaly, and other neurodevelopmental injuries [60].  
 
Figure 12: ZIKV tissue and cell tropism [60] 
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Diagnosis, treatment, and prevention of ZIKV 
Laboratory diagnosis of ZIKV infection in humans is typically performed by detection of 
viral nucleic acid in the serum using qRT-PCR [29]. CDC currently recommends that for 
all symptomatic patients serum and urine samples should be obtained and tested via 
qRT-PCR [74]. However, as viremia is transient in most affected individuals, diagnosis by 
qRT-PCR is most successful only within one week after the onset of clinical illness [29]. 
As shown in Figure 12, while a positive result via qRT-PCR confirms ZIKV infection, a 
negative result does not exclude the possibility and requires other diagnostic methods to 
rule out infection [59]. Other patient specimens such as saliva and urine have also been 
studied for potential diagnostic value. While urine demonstrates the consistent presence 
of viral RNA for up to two weeks, ZIKV is infrequently detected in saliva [39].  
 
Another well-established diagnostic method is the detection of IgM antibodies in serum 
or CSF by IgM-capture enzyme-linked immunosorbent assay (MAC-ELISA) [29]. 
Generally, IgM appears as viremia declines within the first week after symptom onset and 
persists for several months after infection [29]. Diagnosis by serology is the gold standard, 
however sometimes the results are complicated due to potential cross-reactivity to other 
flaviviruses. For example, a recent ZIKV infection may also evoke a positive MAC-ELISA 
result for DENV. Therefore, as shown in Figure 13, the plaque reduction neutralization 
test (PRNT) is used to differentiate between the two and verify MAC-ELISA results [29]. 
In general, a PRNT >10 for ZIKV and <10 for DENV indicates a recent ZIKV infection [75]. 
In ZIKV endemic areas, asymptomatic pregnant women should undergo IgM testing as 
part of routine obstetric care in the 1st and 2nd trimester [74].  
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Figure 13: Algorithm for the laboratory diagnosis of Zika virus infection [59] 
 
As with other mosquito-borne flaviviruses treatment for uncomplicated ZIKV infection is 
largely focused on symptoms as there is no specific antiviral available for use in humans 
[29]. Strategies of care include the use of analgesics such as acetaminophen (Tylenol) to 
reduce fever and combat pain, antiemetics, and rehydration for nausea and vomiting [76]. 
It is also suggested for patients to not take aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDS) until dengue can be ruled out to reduce the risk of bleeding 
[76]. It is also recommended that patients get plenty of rest. For patients experiencing 
GBS, patients should be hospitalized and closely monitored. Additional treatments such 
as plasma exchange to remove antibodies can help improve symptoms and shorten the 
duration of GBS [61]. 
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There is no vaccine currently available for ZIKV, therefore prevention and control 
measures are centered on avoiding mosquito bites, reducing sexual transmission, and 
controlling the mosquito vector [29]. Current CDC recommendations suggest that women 
who have been exposed to ZIKV wait at least 8 weeks from symptom onset before 
attempting conception. Men with possible ZIKV exposure should use condoms or abstain 
from sex for at least 6 months [77]. Health care providers should counsel couples that 
correct and consistent use of condoms reduces the risk for sexually transmitted diseases 
and discuss the use of the most effective contraceptive methods that can be used 
correctly and consistently [42].	 Other preventative measures include using mosquito 
repellent and permethrin treatment for clothing, bed nets, window screens, and air 
conditioning. However, the most effective A. aegypti vector control relies on elimination 
of mosquito breeding sites, in addition to application of larvicides, and insecticides to kill 
adult mosquitoes [29].  
 
Vaccine and antiviral Development 
Development of an effective vaccine to prevent ZIKV infection in high-risk populations is 
an area of intense investigation. Several companies, research organizations, and 
academic institutions, as listed in Figure 14, are actively working on ZIKV vaccine 
development using different methods [78].  While the platforms employed by these 
developers vary, majority of the candidates are based on strategies that have been 
developed for other related flaviviruses and include use of live attenuated virus, whole 
inactivated virus, and subunit recombinant proteins. 
	 27	
 
Figure 14: Proposed ZIKV vaccine candidates/platforms [78] 
 
One example includes the National Institutes of Health (NIH) live-attenuated chimeric 
ZIKV vaccine, which is based on the components of their live-attenuated tetravalent 
dengue vaccine. Specifically, this vaccine candidate is comprised of the prM and E 
proteins of ZIKV combined with the nonstructural proteins of DENV-2 and is expected to 
begin Phase 1 clinical trials soon [78]. Should the vaccine prove to be immunogenic in 
Phase 1 clinical evaluation, NIH hopes to combine this ZIKV vaccine with their live 
attenuated tetravalent dengue vaccine to create a pentavalent vaccine that would be 
administered to children in endemic areas [78].  
 
Another approach is a purified inactivated Zika vaccine under development by the Walter 
Reed Army Institute of Research (WRAIR) called ZPIV. This vaccine is based on a similar 
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approach in which WRAIR used to develop a vaccine against JEV and has entered phase 
1 clinical trials [79]. This type of vaccine generally requires multiple doses and very high 
virus titers/quantity of protein to induce a protective immune response. 
 
Newer strategies such as DNA and subunit vaccines are also under development 
[78]. For example, Inovio Pharmaceuticals is developing a DNA vaccine (GLS-5700), 
which has received approval from the FDA to begin Phase 1 clinical trials [78].  This 
vaccine specifically contains a single plasmid with DNA encoding for the ZIKV pre-
membrane (prM) and envelope (E) proteins. NIAID has developed a similar DNA vaccine 
(entitled VRC 705), which just entered a Phase 2 clinical trial in seven countries [79]. 
Subunit vaccines strategies include expression of various portions of ZIKV E protein in 
both bacterial and insect cell lines. The benefit of subunit vaccines is the ability to produce 
robust immunity to specific antigenic epitopes [80]. Although these vaccine candidates 
are still in pre-clinical stages, they have demonstrated robust protection in mouse and 
NHP models. 
 
There are also several mRNA vaccines under development at GlaxoSmithKline (GSK), 
University of Pennsylvania, and Moderna/Valera. These vaccines utilize lipid-
nanoparticles to deliver nucleoside-modified mRNA encoding ZIKV prM and E proteins. 
The Moderna/Valera candidate is currently being evaluated in a Phase 1 trial [79].  
 
In terms of antivirals, there is currently no clinically approved therapy for ZIKV available. 
However, two strategies are currently being pursued for antiviral development. These 
	 29	
include repurposing existing clinical compounds that have previously been developed for 
unrelated diseases, in addition to discovering new bonafide inhibitors of ZIKV replication. 
In particular, nucleoside/nucleotide inhibitors have shown efficacy against flaviviruses 
[81].  One drug in particular, NITD008, has been demonstrated to be effective against 
suppressing peak viremia, reducing cytokine elevation, and preventing death in vivo 
against DENV, WNV, and ZIKV [82-84]. Furthermore, NITD008 has good in vivo 
pharmacokinetic properties and is biologically available through oral administration [82]. 
While there are no current clinical studies ongoing with anti-flaviviral drugs, 
nucleoside/nucleotide inhibitors may prove to be beneficial and warrants further study.   
 
Host response to ZIKV 
Several recent studies have used in vitro and animal models to delineate specific host 
responses to ZIKV and its comparison to other flaviviruses. Upon introduction of ZIKV via 
an infected mosquito, skin fibroblasts, epidermal keratinocytes, and dendritic cells are 
some of the first cell types to encounter the virus. One of the characteristic features of 
early host response to ZIKV is the induction of robust innate immune pathways such as 
production of antiviral type I IFN and inflammatory cytokines. In primary human skin 
fibroblasts, ZIKV has been shown to induce the expression of pattern recognition 
receptors (PRRs) such as TLR3, RIG-I, and MDA5 that are involved in the recognition of 
ZIKV dsRNA intermediates. Recognition of ZIKV dsRNA by these PRRs activates 
downstream signaling, which results in the production of IFN-α, IFN-β, and transcription 
of several interferon stimulated genes (ISGs), including OAS2, ISG15, and MX1 [27]. 
Additionally, ZIKV-induces pro-inflammatory cytokines (IL-1 β and IL-6) and chemokines 
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(CCL5, MCP-1, and CXCL10) in many cell types [27, 85].  In vitro, several cell types are 
shown to elicit antiviral responses such as human fibroblasts, monocytes, dendritic cells, 
human placental macrophages, skin epithelial cells, retinal cells, and neural progenitor 
cells [27, 73, 85-88]. However, ZIKV-induced downstream effects vary in different cell 
types. On one hand it causes apoptotic cell death in neurons, neuronal progenitor cells 
and retinal epithelial cells, but on the other hand, specific endothelial cells are resistant 
to virus-associated cell death. Studies are still ongoing to determine the precise role of 
ZIKV-induced innate immunity in host protection vs. virus pathogenesis. 
 
The role of type I IFN and ISGs is to control virus replication and spread to neighboring 
cells, and like other flaviviruses, ZIKV is sensitive to the antiviral effects of both type I and 
type II Interferons [27]. Mouse models have further confirmed this finding, as  Ifnar1-/- 
mice and Irf3-/-/Irf5-/-/Irf7-/- triple knockout mice develop high viremia, neurological disease, 
and succumb to ZIKV infection, whereas wild-type (WT) mice do not [89]. IFN 
transmembrane proteins (IFITMs) specifically IFITM1 and IFITM3 have also been shown 
to inhibit ZIKV infection [59]. Although the exact mechanism of IFTM-mediated restriction 
is unknown, experimental approaches suggest that IFITMs can halt ZIKV early in the viral 
replication cycle and prevent cell death [90]. 
 
Lack of a reliable mouse model has hampered progress in our understanding of host 
response to ZIKV. Although ZIKV infection does cause disease in an age-dependent 
manner in WT C57BL/6 mice, the resulting viremia is short-lived from about 1-3 days [89]. 
Since these models have significant limitations in terms of biological relevance, guinea 
	 31	
pig and NHP models have been utilized to provide critical information about tissue tropism 
and host response to the virus [91, 92]. In rhesus macaques, ZIKV infection causes an 
increase in CD169+ monocytes, DCs, and CD16+ natural killer cells in the plasma during 
early infection, which is similar to the monocytosis observed early during DENV and WNV 
infection in humans [71, 93]. ZIKV infection also induced an upregulation of IL-1RA, MCP-
1, CXCL-10, and CXCL-11 cytokines and chemokines as compared to the controls in the 
plasma of NHPs [71].  
 
Other innate immune responses to ZIKV include inflammasome and complement 
activation. Specifically, in glial cells, ZIKV activates the NLRP3 inflammasome and 
subsequently releases mature Il- 1β after infection [94]. Previous studies have shown that 
complement demonstrates protective effects against flaviviruses through direct 
inactivation of virions, activating monocytes and other granulocytes by C3a/C5a, 
opsonization of viral particles by C3b, and lysis of enveloped viral particles and infected 
cells by the membrane attack complexes (MACs) [95]. This pathway for ZIKV however is 
yet to be studied. 
 
Clearance of ZIKV is also mediated by both humoral and cellular immune responses. In 
both mouse and NHP models, proliferating CD4+ and CD8+ T-cells can be detected 
within the first week of infection [71, 96]. Additionally, the number of circulating 
plasmablasts also expands during this time. In NHPs, ZIKV IgM becomes detectable 
between 7-10 dpi with IgG following between days 8-21 dpi. These neutralizing antibodies 
are directed towards the ZIKV E protein, which is consistent with antibody responses 
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against other flaviviruses [71]. Interestingly, prior infection with ZIKV from an Asian-
lineage seems to protect against heterologous infection with an African strain 
demonstrating similar cross-neutralizing epitopes between the two strains [60]. 
 
This antibody response, however, may be complicated in patients who live in both ZIKV 
and DENV endemic areas. For example, due to the high degree of structural and 
sequence similarity between ZIKV and DENV, antibodies produced against these two 
flavivurses can interact with each other. This event is known as antibody-dependent 
enhancement (ADE) and is believed to promote infection of myeloid cells, leading to 
increased disease severity [60]. Cross-reactive anti-DENV antibodies can enhance ZIKV 
infection in cell culture and reciprocally, cross-reactive human anti-ZIKV antibodies can 
promote DENV infection in vitro and in mice [97, 98]. It however remains unknown 
whether ADE of ZIKV by anti-DENV antibodies occurs in humans and further studies are 
warranted to improve our understanding of cross-reactivity between ZIKV and DENV 
antibodies.  
 
Immune evasion of ZIKV 
Flaviviruses, including DENV, have evolved several mechanisms to counteract the host 
antiviral response. In ZIKV, the studies are limited, however they show that ZIKV NS5 
has the ability to modulate the type I interferon signaling pathway through antagonism of 
STAT1 and STAT2 phosphorylation [85]. Additionally, ZIKV NS1 and NS4B have been 
shown to interact with TBK1 to inhibit production of IFN and NS2B-NS3 can inhibit the 
JAK-STAT pathway by degradation of Jak1 [99]. NS2B3 is also reported to attenuate RIG 
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like receptor (RLR)-induced apoptotic death [99]. Recently, it has been shown that ZIKV-
infected human DCs, could not induce expression of CD80/86, which was coupled with 
decreased production of inflammatory cytokines/chemokines suggesting that ZIKV can 
block the innate-adaptive interface [85]. Other immunomodulatory capabilities of ZIKV 
included the downregulation of NF-kB activation through TLR3 and IL-1 receptor 
pathways [71] and inhibition of complement mediated MAC formation on cell membranes 
through ZIKV NS1 protein [100]. Finally, also like DENV, ZIKV is known to hijack 
autophagy to support viral replication, which has been demonstrated in human skin 
fibroblasts and fetal neural stem cells [27, 101].  
 
Overview of the male reproductive tract 
Since ZIKV is associated with sexual transmission and persistence in seminal fluid, 
understanding the normal functioning of the male reproductive tract is important for this 
study. As shown in Figure 15, the human male reproductive tract is composed of several 
different organs that interact to produce sperm cells and transfer them to the female 
reproductive tract. The paired testes are a crucial component to this process as they 
produce both sperm and androgens, such as testosterone. In close association with the 
testes is the epididymis, which is where sperm cells mature, develop the motility, and are 
stored until ejaculation. To be released, sperm must next pass through a long tube from 
the testes to the prostate gland called the Vas Deferens. Although the evidence of ZIKV 
infection in the male human reproductive tract is limited, ZIKV RNA has been detected in 
the testes, prostate, and seminal vesicles of NHPs  [5].  
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Figure 15: Anatomy of the male reproductive system [102] 
 
Mammalian testicular anatomy and spermatogenesis 
Based on the epidemiologic evidence that ZIKV RNA persists in seminal fluid even after 
the virus has been cleared from the blood suggests that it is able to establish a persistent 
infection in the male reproductive tract. As the testes are the site of spermatogenesis and 
are sheltered from peripheral immune responses, they may represent a likely reservoir. 
As shown in Figures 16 and 17, the mammalian testes are specifically divided into two 
compartments, the peritubular compartment (aka interstitial space) and the seminiferous 
tubules. The peritubular compartment specifically consists of blood vessels, testosterone 
producing Leydig cells, and testicular macrophages, while seminiferous tubules contains 
Sertoli cells (SC) and is the site of spermatogenesis [103]. The process of 
spermatogenesis is further depicted in Figure 16. 
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Figure 16: Overview of spermatogenesis [102] 
 
Spermatogenesis begins with the mitosis of the diploid spermatogonia, resulting in two 
identical diploid cells. While one of these cells remains a spermatogonium, the other 
becomes a primary spermatocyte (PSc), which must undergo meiosis to produce haploid 
secondary spermatocytes (SSc). Another round of meiotic division in SSc results in a total 
of four cells with half the number of chromosomes called spermatids. Finally, a process 
called spermiogenesis then reduces the cytoplasm and begins the development of 
structures found in formed sperm also known as spermatozoa. One production cycle from 
spermatogonia through mature sperm, takes approximately 64 days [102]. 
As shown in Figure 17, spermatogenesis occurs within seminiferous tubules, which are 
separated from the peritubular compartment by the blood-testes barrier, also known as 
the Sertoli-cell barrier (SCB) [103]. The SCB mainly functions to protect developing germ 
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cells from systemic attack by adaptive immune cells and cytotoxic molecules, while 
simultaneously providing nutritional and structural support [104]. It represents one of the 
tightest blood-tissue barriers in the human body and is constituted by tight junction 
proteins (TJP) (eg. ZO-1, occludin, claudins) and adherens junction proteins (β-catenin 
and JAM- A) between connecting SC as shown in Figure 17 [103]. These junctions are 
unique compared to other epithelial tight junctions in that they are located basally rather 
than apically [104].  
 
 
 
 
 
 
 
 
 
 
Figure 17: Cross section of the mammalian testes [105]. MPC= myoid peritubular cells,   
Sg= spermatogonia, PSc= primary spermatocytes, SSc= secondary spermatocytes, SS= secretion 
substances, RS= round spermatids, ES= elongating spermatids, BTB= blood-testes barrier, DC= dendritic 
cells, MC= mast cells, BV= blood vessels, MΦ= macrophage 
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In addition to forming an anatomical barrier, SC also contribute to the overall immune-
privileged nature of the testes by participating in local production of anti-inflammatory 
cytokines and immunosuppressive factors, further aided by Leydig cells, testicular 
macrophages, and regulatory T cells [104]. However, upon exposure to viral infections, 
SC have also been shown to induce both innate immune and pro-inflammatory responses 
[3, 106, 107]. The subsequent production of inflammatory mediators associated with the 
disruption of blood-tissue barriers, such as TNF-α, matrix metalloproteinases (MMP), and 
cell- adhesion molecules (CAM) by SC and other testes resident cells are proposed to 
mediate degradation of tight junctions between the SCB allowing pathogens to enter the 
protected adluminal compartment of the seminiferous tubules. Our objective, described 
in chapter two is therefore based on these features of the SCB. 
Literature on testicular infection of ZIKV 
Although the evidence of ZIKV infection in the male human reproductive tract is limited, 
mouse and NHP models provide strong evidence that ZIKV is able to target the male 
reproductive tract. Specifically, in NHPs, ZIKV RNA has been detected in the testes eight 
days after infection and in seminal fluid (plasma) for up to three weeks [4, 5]. ZIKV RNA 
has also been detected in the prostate, seminal vesicles, and testes of NHPs via in situ 
hybridization [5]. Additional data has been obtained utilizing an immunocompromised 
mouse model [89]. While wild type mice do not develop disease symptoms, persistent 
testicular infection for up to 42 days has been documented in mice lacking functional IFN-
α/β receptors (IFNAR1 deficient mice) [2]. These mouse studies have further 
demonstrated presence of ZIKV in the Leydig cells, Sertoli cells, and spermatogonia [2]. 
Infection of murine Sertoli and Leydig cells in vitro also lead to an upregulation of major 
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pro-inflammatory cytokines such as TNF-α, IL-6. IFN-β, and CXCL10 suggesting that they 
play an essential role ZIKV pathogenesis within the testes [3]. Further, infection in 
immunocompromised mice is associated with a destruction of testes architecture, 
decrease in sex hormones, reduction of motile sperm count, and even leads to male 
infertility [2, 3]. Although these in vivo findings are derived from severely 
immunocompromised mouse models and such severe testicular injury is yet to be 
documented in humans or NHPs, they do form the basis of this study to understand 
human testicular ZIKV infection.  
Figure 18: ZIKV infection and pathogenesis in the male reproductive tract 
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Recap of background: Zika virus is a re-emerging flavivirus with increased disease 
severity 
Zika virus (ZIKV), a largely neglected mosquito-borne virus belongs to the flavivirus genus 
of the Flaviviridae family, which includes other globally relevant arthropod-transmitted 
human pathogens such as dengue (DENV), West Nile (WNV) and Japanese encephalitis 
(JEV) viruses [110]. Similar to these related viruses, ZIKV is an enveloped, spherical 
particle with a linear, positive sense RNA genome roughly 10.7 kilobases in length [110]. 
Originally identified as an isolate from rhesus monkeys in the Zika forest in Uganda in 
1947, for half a century, fewer than 20 mild-febrile human infections were documented 
[16]. The first large reported outbreak of ZIKV occurred on the Western Pacific island of 
Yap in 2007 followed by an even larger epidemic in French Polynesia in 2013-2014. 
However, it wasn’t until it made landfall in South America in 2015 that the virus truly began 
to emerge on the global stage, especially due to its associations with more severe 
complications including Guillain-Barré syndrome (GBS) and severe fetal abnormalities 
such as microcephaly [15, 16, 111, 112]. Since 2015, fifty-nine countries and territories 
have reported an outbreak of mosquito-borne ZIKV transmission. Furthermore, 29 
countries have reported microcephaly, other CNS malformations, and incresed incidence 
of GBS potentially associated with ZIKV infection [17].  
	
An update of ZIKV sexual transmission: 
Similar to DENV, WNV, and JEV, ZIKV is primarily transmitted by mosquitos. However 
unlike other related viruses, ZIKV has caught the world’s attention because of two 
unexpected disease transmission routes. First, in utero transmission suspected to be 
associated with dramatic surge in microcephaly cases and second, sexual transmission 
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mainly from infected males to their partners. In the US alone, there have been 1,883 
pregnancies with laboratory evidence of possible ZIKV infection and 46 confirmed cases 
of sexual ZIKV disease transmission [17]. Furthermore, 12 other countries have also 
reported male-to-female sexual transmission [1]. 
These unanticipated routes have led the Center for Disease Control and Prevention 
(CDC) to issue an advisory to pregnant women to consider all possible options to protect 
their pregnancy [33, 113]. Based on reports of ZIKV in the seminal fluid and sperm of 
several male patients [36, 108, 114], it appears that the virus can be spread by males 
before disease symptoms start, when disease symptoms are present, and after the 
symptoms end [36, 115]. There is also mounting evidence that the virus is able to 
establish a persistent infection within the male reproductive tract, specifically within the 
seminiferous tubules of the testes, where sheltered sperm is produced.  
Although the contribution of sex in disease transmission may be difficult to predict in ZIKV 
endemic regions, it certainly complicates the virus epidemiology in regions where the 
mosquito vector is absent. Given the strong evidence of ZIKV in human seminal fluid even 
after the clearance of viremia, and lack of any approved treatment option, it has become 
critically important to understand the mechanisms associated with testicular infection.  
Gap, rationale, and hypothesis: 
Despite the clinical observations and animal findings described in the previous chapter 
little is known about ZIKV infection in the male reproductive tract, which has left many 
questions unanswered. For example, what is the association of the level of viremia with 
testicular invasion of ZIKV? What are some of the host factors that affect persistence of 
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the virus in seminal fluid? Does the viral load in the semen differ between symptomatic 
and asymptomatic men? Efforts to address these questions, however, are hindered 
because of a large gap in our understanding of the specific cell types that support ZIKV 
infection in the human testes and the mechanisms by which the virus establishes 
persistent infection in the immune-privileged seminiferous tubules. Further, absence of 
appropriate tools limits studies to understand virus transmigration kinetics across the 
SCB. Therefore, the objective of this study is to characterize ZIKV replication kinetics and 
immune response in primary Human Sertoli cells (HSEC) and develop an in vitro SCB 
model to understand mechanisms of ZIKV transmigration across the SCB.  
Hypothesis: We hypothesize that ZIKV can productively infect HSEC and macrophages 
and induce robust immune response that can collectively affect the integrity of the blood-
testes barrier model.  
Specific Aim 1: To determine virus replication kinetics and immune response in 
HSEC and macrophages following ZIKV infection  
Rationale: To be able to sexually transmit for weeks after clearance of viremia, it is 
important for ZIKV to establish a persistent infection locally in the compartment where 
spermatozoa development occurs. A recent study with data from 150 newly-infected 
human participants has shown the median time until the loss of ZIKV RNA in the serum 
is around 14 days compared to 34 days in seminal fluid [39]. The rationale for this aim is 
based on mouse studies that show presence of ZIKV RNA in the testes peritubular myoid 
cells, SC, and germ cells [2, 3]. However, the cell tropism of ZIKV in humans has yet to 
be characterized. Although ZIKV has been shown to infect human placental macrophages 
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(Hofbauer cells) [86], ZIKV infection in human peripheral macrophages is not yet 
described. Therefore, we hypothesize that ZIKV can sustain a robust infection in human 
SC and macrophages, induce production of pro-inflammatory mediators including type I 
IFN and cytokines, and alter markers of SCB integrity.  
Objective:  
• Determine the replication kinetics of ZIKV, DENV-2, and WNV in HSEC at different 
multiplicity of infections (MOIs).   
• Define the ZIKV infection kinetics and inflammatory response in human 
monocytes-derived macrophages (MDM)   
• Characterize the anti-viral innate immune response and expression of multiple 
CAM and TJP in HSEC following ZIKV infection   
• Test the ability of a known flavivirus inhibitor (NITD008) in preventing ZIKV  
infection in HSEC 
Specific Aim 2: To test the hypothesis that ZIKV infection of SC and macrophages 
can lead to disruption of in vitro SCB model   
Rationale: To further test the consequence of ZIKV infection on virus-transmigration 
across the barrier, we propose to utilize a human in vitro SCB model. In vitro SCB models 
comprising of human and mouse SC have been routinely used to study mechanisms of 
SC function in spermatogenesis and effects of environmental toxins on barrier integrity 
leading to male infertility [116-119], but have so far not been used to examine virus 
transmigration kinetics. This study, for the first time, will use the in vitro SCB model to 
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characterize virus transmigration and to further understand interactions of peripheral 
immune cells with infected SC. Additionally, since macrophages make up the majority of 
immune cells in the mammalian testes and are able to release inflammatory molecules 
capable of affecting the integrity of the SCB, it is imperative to also characterize their role 
in SCB integrity.  	
Objective:   
• Optimize an in vitro SCB model and determine ZIKV transmigration by measuring 
viral titers in the upper (UCS) vs. lower chamber supernatants (LCS)   
• Quantify SCB integrity following ZIKV infection by measuring Trans-endothelial 
electrical resistance (TEER) and through FITC-labeled dextran transmigration 
assays   
• Establish whether ZIKV induced CAM affect interaction of HSEC with leukocytes  
• Determine the effect of MDM-derived inflammatory mediators on SCB integrity  
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Significance:  Since January 1, 2015 there have been 46 confirmed cases of ZIKV 
sexual transmission cases, 72 cases of live born infants with birth defects, and 8 
pregnancy losses with birth defects in the US alone [17]. These disconcerting statistics 
combined with the fact that ZIKV is now associated with severe clinical diseases such as 
microcephaly and GBS highlights the utmost importance of understanding the 
pathogenesis of ZIKV disease and sexual transmission. Furthermore, this route may 
contribute significantly to the disease spread in non-endemic regions such as the United 
States. As seen in animal models and with other testes-tropic pathogens, the possibility 
of ZIKV causing testicular pathology and male infertility also exists. So far there are no 
antiviral drugs approved to specifically target ZIKV infection, therefore NIH has identified 
sexual transmission of ZIKV as a high priority research area. The data obtained from this 
study will be significant because it will identify one of the potential routes ZIKV may utilize 
to establish persistence in to the testes. Additionally, given the recent evidence of Ebola 
virus RNA in seminal fluid for 6 to 9  months after clearance of acute infection [49], it has 
become critically important to understand the mechanisms by which these pathogens 
hide in the immune privileged site of testes and infect developing spermatozoa for months 
after clearance of viremia. Novel insights into these mechanisms will properly inform CDC 
and WHO health policies. Furthermore, use of in vitro SCB models to test the ability of 
new antiviral drugs to cross the SCB may also impact the development of novel 
therapeutic strategies to clear testicular infection of ZIKV and other viruses.  
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Chapter 3 
Zika virus infects human sertoli cells and modulates the 
integrity of the in vitro blood-testes barrier model 
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Abstract 
Confirmed reports of ZIKV in human seminal fluid for months after the clearance of viremia 
suggest the ability of ZIKV to establish persistent infection in the seminiferous tubules, an 
immune privileged site in the testes protected by the blood-testes barrier, also called the Sertoli 
cell barrier (SCB). However, cellular targets of ZIKV in human testes and mechanisms by which 
the virus enters seminiferous tubules remain unclear. We demonstrate that primary human SC 
are highly susceptible to ZIKV as compared to the closely related dengue virus and induced 
expression of IFN-α, key cytokines and cell-adhesion molecules (VCAM-1 and ICAM-1). 
Further, using an in vitro SCB model, we demonstrate that ZIKV was released on the adluminal 
side of the SCB model with higher efficiency as compared to the blood-brain barrier. ZIKV-
infected SC exhibited enhanced adhesion of leukocytes that correlated with decrease in the 
SCB integrity. ZIKV infection did not affect the expression of tight and adherens junction 
proteins such as ZO-1, claudin and JAM-A, however exposure of SC to inflammatory mediators 
derived from ZIKV-infected macrophages led to the degradation of ZO-1 protein that correlated 
with increased SCB permeability. Taken together, our data suggest that infection of SC may 
be one of the crucial steps by which ZIKV gains access to the site of spermatozoa development 
and identify SC as a therapeutic target. Further, the SCB model opens up opportunities to 
assess interactions of SC with other testicular cells and test the ability of anti-ZIKV drugs to 
cross the barrier and clear testicular infection. 
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Importance 
Recent outbreaks of ZIKV, a neglected mosquito-borne flavivirus, have identified sexual 
transmission as a new route of disease spread, not reported for other flaviviruses. To be 
able to sexually transmit for months after clearance of the viremia, ZIKV must establish 
infection in the seminiferous tubules, a site for spermatozoa development.  However, little 
is known about the cell types that support ZIKV infection in the human testes. Currently 
there are no models to study mechanisms of virus persistence in the seminiferous tubules. 
We provide evidence that ZIKV infection of human Sertoli cells, important component of the 
seminiferous tubules, is robust and induce strong antiviral response.  The use in vitro Sertoli 
cell barrier to describe how ZIKV or inflammatory mediators derived from ZIKV-infected 
macrophages compromise the barrier integrity will enable studies to explore interaction of 
other testicular cells with Sertoli cells and test novel antivirals for clearing testicular ZIKV 
infection 
 
Introduction: 
Zika virus (ZIKV), a largely neglected arbovirus belongs to the flavivirus genus of the 
Flaviviridae family, which includes other globally relevant arthropod-transmitted human 
pathogens such as dengue, West Nile (WNV) and Japanese encephalitis (JEV) viruses.  
Recent re-emergence of ZIKV in the South Pacific and Latin America in 2015-2016 has 
been associated with more severe complications including Guillain-Barré syndrome and 
severe fetal abnormalities [16]. So far, 38,527 locally acquired cases have been reported 
in the U.S including American Samoa, U.S. Virgin Islands and Puerto Rico [17]. However, 
what caught the world’s attention during the recent ZIKV outbreak was the two unexpected 
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disease transmission routes: first, in utero transmission associated with a dramatic surge 
in microcephaly cases and second, the sexual transmission from infected males to their 
partners. In the US alone, 46 cases of ZIKV disease transmission via the sexual route has 
been confirmed so far [17] and at least 12 other countries have also reported male-to-male 
and male-to-female transmission, leading to an urgent advisory to pregnant woman to 
consider all possible options to protect their pregnancy [1]. Based on reports of the duration 
of the presence of ZIKV in the seminal fluid, it appears that the virus can be spread by 
males before disease symptoms start, when disease symptoms are present, and after the 
symptoms end [36, 115]. Further, it is unclear if infected individuals who remain 
asymptomatic can also sexually transmit ZIKV, and if there is any association of the level 
of viremia with testicular invasion of ZIKV. Although the contribution of the sexual route in 
disease transmission may be difficult to predict in ZIKV endemic regions, it certainly 
complicates the virus epidemiology in non-endemic regions where the mosquito vector is 
absent. A recent cohort study reported that 56% of the ZIKV serum-positive males were 
also positive for the virus in the semen and the median time until the loss of ZIKV RNA in 
the semen was 34 days as compared to 14 days in the serum thus suggesting a much 
longer infectious phase of ZIKV as compared to other flaviviruses traditionally transmitted 
via mosquitoes [39]. Considering the lack of any measures approved to clear ZIKV infection 
and the detection of RNA of other re-emerging pathogens such as Ebola virus in the semen 
[36, 49], it has become critical to understand the mechanisms associated with testicular 
infection of ZIKV.  
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The mammalian testes are divided into two compartments, the peritubular compartment, 
which consists of Leydig cells and testicular macrophages, and the seminiferous tubules 
compartment with germ cells protected by Sertoli cells (SC).  These SC form the blood-
testes barrier, also known as the Sertoli-cell barrier (SCB) that mainly functions to protect 
developing germ cells from systemic attack by adaptive immune cells, while simultaneously 
providing nutritional and structural support [103, 104]. As one of the tightest blood-tissue 
barriers, the SCB is formed by tight junction proteins (TJP) complexes such as ZO-1, 
occludin, and claudins, as well as adherens junction proteins between connecting Sertoli 
cells [103]. Similar to other blood-tissue barriers such as blood-brain barrier (BBB), in 
addition to providing a physiologic barrier, SCB also participates in the immune response 
to invading pathogens. Several viruses including mumps virus have been shown to infect 
human testes and induce inflammatory mediators associated with the disruption of blood-
tissue barriers including TNF-α, type I IFN, matrix metalloproteinases (MMP) and cell-
adhesion molecules (CAM) [107]. 
 
The data on testicular infection of ZIKV in humans is limited, however mouse and 
nonhuman primate models of ZIKV infection provide strong evidence of persistent ZIKV 
replication in the testes. Immunocompetent mice do not develop disease symptoms, but 
persistent testicular infection for up to 45 days in IFNAR1 deficient mice has been 
associated with pro-inflammatory responses, infiltration of leukocytes into the testes, and 
damaged architecture of the seminiferous epithelium [2, 3]. Similarly, nonhuman primate 
studies have also reported presence of ZIKV RNA in the testes at 7-8 days after infection 
[5]. In humans, not all, but some ZIKV-infected men present with hematospermia, however 
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presence of virus in the semen even after the clearance of the viremia suggests that sexual 
transmission is not the result of hematospermia-induced blood-borne transmission and that 
ZIKV has the ability to establish persistent testicular infection. However, little is known about 
the cell types that support ZIKV infection in testes and currently there are no models that 
can be used to study mechanisms by which the virus establishes persistence in the 
seminiferous tubules.  Here, we show that primary human SC are highly susceptible to 
ZIKV infection as compared to dengue virus and are capable of inducing robust antiviral 
immune and inflammatory responses. We further developed an in vitro SCB model to 
systematically investigate whether ZIKV can be released on the adluminal side of the SCB 
and test how ZIKV infection of SC and macrophages affects barrier integrity. We 
demonstrate that ZIKV can cross the in vitro SCB more efficiently as compared to the BBB 
model without altering barrier permeability and expression of junction proteins. However, 
inflammatory mediators secreted from ZIKV-infected macrophages compromised the 
barrier integrity. Our data suggest that infection of SC may be one of the crucial steps by 
which ZIKV gains access to immune privileged seminiferous tubules and may serve as a 
reservoir for infection of other resident testicular cells including developing spermatozoa. 
 
Results	
ZIKV can infect and replicate in human Sertoli cells 
Since SC are the primary component of the SCB that protects entry of pathogens into the 
seminiferous tubules, we first determined if primary Human Sertoli cells (HSEC) were 
susceptible to ZIKV.  Low passage HSEC were infected with ZIKV strain PRVABC59 at a 
multiplicity of infection (MOI) of 1 and 5, and virus replication kinetics was analyzed using 
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multiple virological assays. As seen in Fig. 1, while no ZIKV titers were detected at 6 hrs 
after infection, titers reached about log 4.5 PFU/mL in supernatant at 24 hrs after infection 
and further peaked at 48 and 72 hrs after infection. Intracellular ZIKV replication also 
followed a similar trend wherein peak RNA levels were observed at 48 hrs after infection. 
However, we did not observe any cytopathic effect or cell death (Supplemental Figure 1). 
Further confirmation of the HSEC susceptibility to ZIKV by immunostaining using flavivirus 
specific 4G2 antibody demonstrated a robust signal of ZIKV-bound antibody in HSEC at 48 
hrs after infection (Fig. 1C). Since ZIKV is also a neurotropic virus [89], we next compared 
the infectivity of ZIKV in HSEC vs. human brain microvascular endothelial cells (HBMVEC), 
a major component of the BBB. ZIKV titers in the supernatants from primary HBMVEC 
demonstrated similar replication kinetics as observed in HSEC. However, peak viral titers 
were almost half a log lower as compared to HSEC at 72 and 96 hrs after infection and this 
difference was statistically significant (p<0.05, Fig. 1D). We also compared the relative 
infection of ZIKV, West Nile virus (WNV), and dengue virus 2 (DENV2) in HSEC at different 
MOIs. As seen in Fig. 1E and Supplemental Fig. 2, DENV replication was not detected at 
24 hrs and the titers were 3 logs lower than ZIKV titers at 48 and 72 hrs after infection 
(p<0.05). However, interestingly SC supported robust infection of WNV and the virus titers 
were comparable to ZIKV at all time points (Fig. 1E). These data suggest that while ZIKV 
can infect both HSEC and HBMVEC, virus replication is lower in HBMVEC and that HSEC 
are not a good target of dengue virus.   
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Fig. 1. ZIKV infection in human Sertoli cells is productive. HSEC were infected with 
ZIKV and (A) Virus titers were quantified by plaque assay using Vero cells and expressed 
as PFU/mL supernatant. (B) ZIKV mRNA determined using qRT-PCR and expressed as 
PFU equivalent/μg RNA (C) Representative image of ZIKV immunostaining in infected 
HSEC at 48 hrs after infection at MOI1. Cells were immunostained for envelope protein 
(green) using the 4G2 anti-flavivirus group antibody, secondary antibody alone and nuclei 
using DAPI (blue). (D) HSEC and HBMVEC were infected with ZIKV at MOI1 and titers 
were measured by plaque assay. (E) HSEC were infected with ZIKV, WNV, and DENV 2 
(MOI1) and viral titers at different time points were measured using plaque assay. Error 
bars represent SEM of at least 3-5 independent infections. *, p<0.05 and **, p<0.01 
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ZIKV infection induces type I IFN signaling and inflammatory cytokines in HSEC 
Robust production of type I IFN and inflammatory cytokines is required to restrict virus 
dissemination into immune privileged tissues such as the testes. Therefore, to test whether 
HSEC were capable of initiating antiviral responses to ZIKV, we next measured the levels 
of IFN-α and key antiviral cytokines.  As seen in Fig. 2A, the mRNA transcripts of the key 
IFN-stimulated gene IFIT1 and cytokines (TNF-α and IL-6) were found to be elevated at 48 
and 72 hrs after infection. ZIKV infection did not induce IFN-α secretion during early time 
points, however a robust induction was observed in the supernatant at 48 and 72 hrs after 
infection (Fig. 2B). Furthermore, levels of multiple inflammatory cytokines such as IFN-γ, 
IL-1α, IL-1β, IL-6, IL-8 and TNF-α were significantly elevated in the supernatant at 48 and/or 
72 hrs after infection that correlated well with peak virus titers. The secretion of chemokines 
involved in recruiting leukocytes to inflammatory sites, such as RANTES (CCL5), fractalkine 
(CX3CL1), and IP-10 (CXCL10) were also significantly increased at 72 hrs after infection. 
Interestingly, GRO (growth-related oncogene CXCL1, which is structurally related to IL-8) 
chemokine shown to attract neutrophils and T lymphocytes in the testes during orchitis of 
various origins [120], was also found to be significantly elevated at both 48 and 72 hrs after 
infection (Fig. 2B). Collectively, these results demonstrate that HSEC are capable of 
generating a strong innate immune response to ZIKV infection.  
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Fig. 2. ZIKV infection induces secretion of antiviral and pro-inflammatory mediators 
in HSEC. HSEC were infected with ZIKV at MOI1 and at different time points (A) Total RNA 
extracted from lysates was used to measure relative mRNA fold-change of IFIT1, TNF-α 
and IL-6 as compared to controls by normalizing to GAPDH. (B) IFN-α levels in the 
supernatant were measured by Luminex assay. Secretion of pro-inflammatory cytokines 
(IFN-g, IL-1b, IL-1ra, IL-1a, TNF-a, IL-8, IL-6) and chemokines (RANTES, GRO-
chemokine, and IP-10) in the supernatant at different time points after infection was 
analyzed using multiplex bead-based assay. Error bars represent SEM of at least 3-6 
independent infections for each time point. *, p<0.05 and **, p<0.01 as compared to mock. 
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Effect of ZIKV infection on CAM, MMP and tight junction proteins 
Under healthy conditions SC express very low levels of CAM, however inflammatory 
triggers or infection can induce the expression of multiple CAM and MMP associated with 
degradation of TJP [6, 121]. Therefore, we next determined if ZIKV infection could alter the 
expression of CAM and MMP in HSEC. As seen in Fig. 3A, we observed an increase in the 
mRNA transcripts of vascular cell adhesion molecule 1 (VCAM-1) and intracellular 
adhesion molecules (ICAM-1) but not of E-selectin (data not shown) at 72 hrs after infection. 
Further analysis of CAM using western blotting demonstrated a significant increase in the 
protein levels of VCAM-1, while expression of E-selectin did not change significantly thus 
supporting the qRT-PCR data (Fig. 3B and C). Among key MMP, ZIKV infection did not 
affect the mRNA expression of MMP-1 and MMP-3 (data not shown). Transcription of MMP-
9, however, was modestly upregulated (2-3 fold) at 72 hrs after infection, but this increase 
could not be observed at the protein level (Fig. 3A and B).  
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Fig. 3. Effect of ZIKV infection on cytokines, CAM, and MMP (A) Total RNA extracted 
from ZIKV-infected HSEC lysates (MOI-1) was used to measure relative mRNA fold-change 
of VCAM-1, ICAM-1 and MMP-9 as compared to controls by normalizing to GAPDH. (B) 
Whole cell extracts were subjected to Western blotting and stained for VCAM-1, E-selectin, 
MMP-9 and β-actin. The Western blot is representative of at least three independent 
infections. (C) Percent change in the protein levels as compared to controls measured 
using densitometric analysis and normalized to β-actin. *, p<0.05 as compared to mock 
 
 
Altered gene expression or degradation of tight and adherens junction proteins is one of 
the critical events associated with leakiness of SCB and other tissue-barriers. Therefore, 
we next investigated if ZIKV modulates the expression of key TJP, such as ZO-1, occludin, 
and claudin-1, in HSEC. The mRNA transcripts of ZO-1, claudin-1 and occludin were 
comparable to controls at all time points after infection (data not shown). At the protein level 
also, we observed no change in ZO-1, occludin and claudin-1 expression in HSEC at any 
time points after infection (Fig. 4A). Furthermore, immunocytochemical analysis also 
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exhibited comparable signals of ZO-1 immunostaining in mock- and ZIKV-infected HSEC 
monolayers (Fig. 4C). Similarly, the expression of key adherens junction proteins, β-catenin 
and JAM-A, also did not change at any time points following ZIKV infection (Fig. 4B), thus 
suggesting that direct ZIKV infection of HSEC does not result in degradation of junction 
proteins. 
 
 
 
 
 
 
 
 
 
 
 
	
 
Fig. 4. ZIKV infection does not alter the expression of tight junction and adherens 
junction proteins in HSEC. Total protein extracted from ZIKV-infected HSEC (MOI-1) was 
used to measure levels of (A) TJP (ZO-1, occludin and claudin) and (B) adherens junction 
proteins (β-catenin and JAM-A) and β-actin by Western blotting using specific antibodies. 
The Western blot is representative of at least three independent infections. (C) 
Immunostaining of ZO-1 in mock- and ZIKV-infected HSEC at 48 hrs after infection showed 
comparable ZO-1 signal at the cell borders and cell-to-cell contact sites.  
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Cell free ZIKV is efficiently released on the adluminal side of the in vitro SCB model  
To determine if ZIKV infection of SC represents a route for the virus to enter the 
seminiferous tubules, we utilized an in vitro SCB model using trans-well cell culture PET 
inserts and quantitated the transmigration of ZIKV across the inserts. Since SCB restricts 
the movement of ions, the well-documented methods to assess the tightness of the tissue-
barrier are transendothelial electrical resistance (TEER) and FITC-labeled dextran 
transmigration assays [122, 123]. The SCB permeability was assessed starting at day 4 
after seeding and demonstrated a gradual increase of resistance from 25 to 110-130 Ω/cm2, 
which was comparable to other SCB studies using similar inserts with 0.3 cm2 surface area 
[124]. At day 8 or 10 after seeding, after ensuring TEER >100 Ω/cm2, the SCB model was 
infected with ZIKV or UV-ZIKV at MOIs 1 and 5 and virus titers in the upper chamber 
supernatant (UCS) representing the peritubular side of the SCB and lower chamber 
supernatant (LCS) corresponding to the lumen of seminiferous tubules were determined at 
different time points. Very low levels of ZIKV were detected at 6 hrs after infection, which 
represented the residual inoculum after gentle washing of the inserts (Fig. 5A). The 
replication kinetics of ZIKV observed in the UCS was similar to that observed in ZIKV-
infected HSEC monolayers in culture plates (Fig. 1A) and showed a marked increase at 24 
hrs and peaked at 48 hrs after infection. ZIKV titers in the LCS were very low at 24 hrs (in 
the same range as at 6 hrs after infection), but a sharp increase to log 4-5 PFU/mL was 
observed at 48 and 72 hrs after infection. However, virus titers in the LCS were 
approximately 1.5 to 2 logs lower than the UCS at all time points (p<0.01), and as expected, 
no plaques were detected in the SCB models infected with UV-ZIKV. We further compared 
ZIKV transmigration across the BBB model prepared as described in our previous studies 
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[122, 123]. As seen in Fig. 5A, ZIKV was detected both in the UCS and LCS at 48 and 72 
hrs infection, but the transmigrated virus in the LCS was significantly lower in the BBB (less 
than log 4 PFU/mL) as compared to SCB models (log 6 PFU/mL). 
 
To assess if ZIKV infection and release in the LCS has any effect on the integrity of the 
SCB model, we next measured the permeability before and at day 3 after infection. The 
TEER values were above 100 Ω/cm2 in all inserts before infection and remained 
comparable at day 3 after infection in both the controls and UV-ZIKV-infected models as 
compared to their respective TEER values before infection. While ZIKV infection at MOI-1 
did not affect the TEER values, we observed a slight reduction in the TEER values in inserts 
infected at MOI-5 as compared to controls (Fig. 5B). Analysis of SCB permeability using 
the FITC-dextran assay also demonstrated that approximately 4.5% of total input FITC-
dextran on the UCS transmigrated to the LCS in control inserts, which increased modestly 
to (5.5) in infected inserts at day 3 of infection, but this difference was not statistically 
significant (Fig. 5C). Similarly, FITC-dextran transmigration (Fig. 5C) and TEER values 
(data not shown) remained comparable in mock and ZIKV-infected (MOI-1) BBB models. 
Collectively, these results demonstrate that while cell-free ZIKV is released on the 
adluminal side of both SCB and BBB models, it does not significantly affect barrier integrity. 
Furthermore, the ability of the virus to transmigrate across the SCB is much higher as 
compared to the BBB. 
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Fig. 5. Cell free ZIKV is efficiently released on the adluminal side of an in vitro SCB 
model without affecting barrier integrity. At day eight after seeding, the upper chamber 
of the (A) in vitro SCB and BBB models were infected with mock, UV-ZIKV and ZIKV, and 
washed gently to remove unattached virus.  The virus titers determined by plaque assay 
demonstrated a significant increase in both, UCS and LCS from days 1 to 3 after infection. 
Data represent mean ± SEM of two independent infection experiments in triplicate. (B) The 
integrity of the SCB model as determined by measuring the TEER at 72 hrs after infection. 
TEER values are presented as Ω/cm2 and did not change significantly after infection as 
compared to controls. The data is representative of at least three independent experiments. 
**p<0.01, compared to LCS (C) FITC-dextran permeability assay of the SCB and BBB 
models at 72 hrs after infection. The percentage of FITC-dextran that crossed the BBB 
model was determined based on the total input FITC-dextran and did not vary significantly 
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in ZIKV or UV-ZIKV infected inserts as compared to un-infected controls. (D) HSEC 
monolayers on the coverslips were infected with ZIKV for 72 hrs and then 2 x 105 
monocytes or PBMCs were added to the cells.  After two hrs of incubation, the non-adhered 
leukocytes were vigorously washed off and adherent cells were stained with CD45 (white 
arrows).  Immunofluorescence micrograph of CD45-stained monocytes. (E) Quantitative 
representation of CD45+ monocytes and PBMCs from six different areas per coverslip from 
at least three independent infections. **p<0.01, compared to mock-infected inserts (F) The 
integrity of the in vitro SCB model was determined by measuring the FITC-dextran 
transmigration after four hrs of incubation with monocytes. *p<0.05, compared to control 
SCB without monocytes incubation.  
 
ZIKV infection increases the adhesion of leukocytes to SC 
Since VCAM-1 and ICAM-1 are the key CAM involved in cell-cell interactions, the first step 
during leukocytes transmigration across epithelial and endothelial cells, we next utilized a 
cell adhesion assay to determine whether ZIKV-infected HSEC exhibited any difference in 
their ability to mediate leukocyte adhesion. As seen in Fig. 5D, while co-culture of naïve 
monocytes with mock-infected HSEC monolayers on coverslips demonstrated only a small 
number of monocytes adhered to the mock-infected HSEC, they increased significantly in 
the infected HSEC (day 3 after infection, p<0.01). We also observed similar results of 
increased adherence of CD45+ PBMCs to the ZIKV-infected HSEC (Fig. 5E). To further 
determine the consequence of leukocyte interaction with the SCB, 250,000 naïve 
monocytes were incubated with the inserts when the induction of CAM by ZIKV was at its 
peak (day 3 after infection). SCB permeability was assessed using FITC-dextran 
transmigration and as seen in Fig. 5F, a significant increase in the percent transmigration 
of FITC-dextran was observed only in the ZIKV-infected inserts incubated with monocytes 
(p<0.05).     
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ZIKV infection in human macrophages induces changes in SCB integrity 
Testicular macrophages are important cell types in the peritubular compartment of the 
testes and are shown to contribute to testicular inflammation [125].  Therefore, we first 
characterized replication kinetics of ZIKV in human macrophages. As seen in Fig. 6A, peak 
ZIKV replication was observed at 24 hrs, however the infection was not as robust as HSEC.  
Peak virus titers were coupled with increased mRNA transcripts of IFN-α and IFIT1 genes 
(Fig. 6B), as well as secretion of multiple inflammatory cytokines including TNF-α, IL-1α 
and IL-8, at 24 and/or 48 hrs after infection. Additionally, ZIKV also induced important 
chemotactic chemokines, such as GRO, IP-10 and MCP-1, at 48 hrs after infection (Fig. 
6C).	 To determine whether ZIKV-induced inflammatory mediators derived from 
macrophages could influence SCB integrity, we conducted experiments using the UV-
inactivated supernatant from either ZIKV- or mock-infected macrophages.  At day 9 after 
seeding, when the TEER readings of the inserts were above 120 Ω/cm2, the SCB models 
were incubated with ZIKV-infected macrophage supernatant collected at 48 hrs after 
infection. While the treatment of inserts with supernatant from mock-infected macrophages 
did not change TEER values or FITC-dextran transmigration as compared to control SCB 
models (only HSEC media), decreased TEER readings were observed in the inserts treated 
with supernatant from ZIKV-infected macrophages that correlated with a significant 
increase in the percentage of FITC-dextran transmigrated to the LCS (Fig. 6 D). In parallel, 
we also incubated naïve HSEC monolayers on coverslips with supernatant from infected 
macrophages for 3 hrs. As seen in Fig. 6E, the intensity of ZO-1 immunostaining reduced 
markedly only in the coverslips treated with TNF-α (positive control) and supernatant from 
ZIKV-infected macrophages at 48 hrs after infection. These results collectively suggest that 
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inflammatory mediators released from ZIKV-infected cells in the peritubular compartment 
possess the potential of disrupting the SCB.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. ZIKV infection in human macrophages induces mediators that alter SCB 
permeability. Human macrophages were infected with ZIKV at MOI1. (A) Culture 
supernatants collected at different time points after infection were used to determine titers 
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using plaque assay on Vero cells. (B) qRT-PCR analysis of IFIT1 and IFN-a in infected 
macrophages. The data are normalized to the values of GAPDH and expressed as relative 
fold increase compared to uninfected controls. (C) Secretion of pro-inflammatory cytokines 
and chemokines in the supernatant was analyzed using multiplex bead-based assay. Data 
represent the mean ± SEM from three independent experiments. *, p<0.05 as compared to 
mock. (D) At day 9 after seeding, HSEC and SCB models were incubated for 2 hrs with 
supernatant from mock- and ZIKV-infected macrophages at 48 hrs time point and TEER 
values, presented as Ω/cm2, demonstrated a decrease only in the inserts incubated with 
either supernatant from infected macrophages. FITC-dextran permeability assay 
demonstrated an increase in transmigration across the inserts incubated with supernatant 
from infected macrophages. *, p<0.05 as compared to inserts with no treatment (E) HSEC 
monolayers on coverslips were incubated with supernatant from mock- or ZIKV-infected 
macrophages (48 hrs time point) and TNF-a as positive control, and immunostained with 
anti-ZO-1 (white arrows).   
 
 
Anti-flavivirus drug NITD008 blocks ZIKV infection in HSEC in a dose-dependent 
manner.  
Current small molecule drugs against flaviviruses include NITD008, a nucleoside analog 
targeting viral polymerases, that has been shown to exhibit potent antiviral activity against 
DENV, WNV and hepatitis C virus, and more recently against ZIKV in Vero cells [83, 84]. 
Therefore, we next evaluated if this drug can block ZIKV replication in HSEC. The HSEC 
monolayers were treated with three different concentrations of NITD008 following ZIKV 
infection at MOI-1 and we observed a dose-dependent inhibition of ZIKV replication as 
demonstrated by plaque assay. In HSEC monolayers treated with 5 μM concentration, 
NITD008 completely blocked ZIKV replication (Fig. 7).   
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Fig. 7. Anti-flavivirus drug NITD008 blocks ZIKV infection in HSEC in a dose-
dependent manner.	HSECs were infected with ZIKV at a MOI 1 followed by the treatment 
with vehicle or indicated concentrations of NITD008. Supernatants collected at different 
time points were used to measure viral titers by plaque assay using Vero cells. The error 
bars represent data from three independent experiments. 
 
Discussion 
Considering a sudden increase in microcephaly cases in the recent ZIKV outbreak, there 
is a significant interest in understanding the pathogenesis of ZIKV in the testes, specifically 
to identify potential targets for intervention. Based on our results using human HSEC, 
macrophages and a relevant in vitro SCB model, we propose that ZIKV infects SC with 
higher efficiency than dengue virus and induces a robust yet balanced antiviral defense 
response with minimal cell death. ZIKV is released on the lumen side of the in vitro SCB 
model with higher efficiency than the blood-brain barrier model without affecting the barrier 
permeability. However, ZIKV-infected HSECs exhibit enhanced adhesion of monocytes, 
most likely via increased expression of CAM, leading to the disruption of SCB. Our results 
	 68	
also highlight the contribution of macrophages in testicular infection of ZIKV and show that 
inflammatory mediators derived from infected macrophages have the potential to 
compromise integrity of the in vitro SCB. Lastly, our study shows that SC can be one of the 
potential targets of anti-flavivirus compound NITD008 and provides an experimental SCB 
model to test future antiviral drugs to clear testicular infections.  
  
The SCB, comprised of SC with unique tight and adherens junctions, is critical to preserve 
the integrity of immune privileged seminiferous tubules by restricting entry of pathogens 
and systemic immune cells, while simultaneously providing support to differentiating germ 
cells. Human SC are shown to be the target of other testes-tropic viruses including mumps 
and HSV [106], but not of HIV and SIV, which are mostly detected in testicular macrophages 
and T cells [126, 127]. However, Govero and colleagues recently reported presence of 
ZIKV RNA in mouse testicular cells including SC, spermatogonia and Leydig cells at day 7, 
which persisted until day 21 after infection in an immunocompromised mouse model [2]. 
Our in vitro data using human SC is in agreement with the mouse data, and suggests that 
human SC are also one of the targets of ZIKV infection. Further, a direct comparison of 
cell-tropism demonstrating significantly reduced replication of DENV in HSEC leads us to 
speculate that striking differences in the susceptibility of SC to ZIKV and DENV may be one 
of the reasons why only ZIKV and not DENV is able to establish persistent infection in the 
testes. Moreover, similar infection kinetics of WNV and ZIKV in SC is not surprising, as 
WNV is known for wide range of cell- and tissue-tropism as compared to DENV. Previous 
studies have reported shedding of WNV in the urine in human patients for months after 
recovery from disease symptoms, however presence of WNV in the seminal fluid of infected 
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humans is not shown so far. Since WNV requires an avian host for amplification of the virus, 
the possibility of human-to-human transmission of WNV via sexual route is relatively low. 
 
Our data showing a robust antiviral defense response to ZIKV including production of IFN-
α and several inflammatory cytokines agree with a recent in vitro study that reported 
production of TNF-α, IL-6 and IFN-β in mouse SC, but not in germ cells or peritubular 
myeloid cells, thus suggesting that SC are one of the major sources of antiviral cytokines 
in human testes [3]. Similarly, Singh and colleagues recently demonstrated that ZIKV 
infection in the cells of blood-retinal barrier is also associated with an antiviral defense 
response [73] suggesting that different blood-tissue barrier cells are able to mount a 
protective response to ZIKV. Given that many pathogen-recognition receptors including 
TLR3 and RIG- I are expressed in SC and that the synthetic dsRNA analogue poly I:C can 
induce cytokine production [128], it is highly likely that detection of ZIKV-derived dsRNA by 
TLR3 and/or RIG-I is one of the upstream pathways associated with the innate immune 
response elicited following infection.  
 
In addition to restricting entry of pathogens and immune cells into the seminiferous tubules, 
another important function of the mammalian SCB is to facilitate movement of developing 
germ cells into the adluminal compartment of the seminiferous tubules. This unique 
mechanism of transit of spermatocytes requires restructuring of the SCB via modulating 
TJP throughout spermatogenesis without compromising the homeostasis of the 
seminiferous tubules [104].  However, cell adhesion molecules such as ICAM-1 and VCAM-
1 and MMP induced by inflammatory triggers including TNF-α and IL-1α play a critical role 
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in junction disruption and cell movement [6]. The pattern of ZIKV-induced response in the 
SCB is very similar to WNV-BBB interaction.  Our previous studies showed that while CAM 
such as VCAM-1 and ICAM-1 were induced by WNV in BBB-endothelial cells and mediated 
leukocyte infiltration in the CNS, the source of MMP involved in the degradation of TJP of 
the BBB were resident astrocytes [122, 123]. Similarly, severity of vascular leakage induced 
by DENV is associated with increased levels of VCAM-1 [129], suggesting a common trend 
of all flaviviruses to induce CAM to facilitate transmigration of peripheral immune cells 
across the barrier.  
 
Histological analysis has revealed intensive damage of mouse seminiferous tubules 
accompanied with diminished populations of SC and infiltration of CD45+ leukocytes in the 
testes at days 14 and 21 after ZIKV infection of mice [2]. A major question that remains is 
what are the mechanisms by which ZIKV and leukocytes gain access to the seminiferous 
tubules and cause infection of developing spermatozoa and/or testicular damage? One 
possible explanation based on our data is that direct infection of SC may represent one of 
the routes of ZIKV entry into the immune privileged compartment of the testes, but this 
process may not directly affect the barrier integrity or cause cell death (Fig. 8). The direct 
consequence of the ZIKV infection of the SC would be to avoid immune detection and be 
a reservoir to infect developing spermatozoa or elongated spermatids in the lumen, thereby 
contributing to the persistence of infection even after clearance of viremia. However, ZIKV 
infection may also increase the susceptibility of the SC to interact with other peritubular 
immune cells most likely via CAM leading to increased infiltration across the barrier and 
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contribute to barrier disruption as one of the mechanisms underlying ZIKV-associated 
damage to the seminiferous tubules.  
 
Circulating monocytes or testicular macrophages in the peritubular compartment regulate 
the testicular immune environment in a manner that provides protection for the developing 
male germ cells, while permitting balanced inflammatory responses and protection against 
infections [125, 130]. However, in experimental autoimmune orchitis and LPS-induced 
murine models of testicular inflammation, activated macrophages are shown to contribute 
to the inflammation, ultimately causing massive infiltration in the seminiferous tubules, 
disruption of barrier junctions, and atrophy of SC [130]. Limited data exists on the infection 
kinetics of ZIKV in human macrophages, although Quicke and colleagues have recently 
documented productive ZIKV infection coupled with inflammatory responses in human 
Hofbauer cells, placental macrophages [86]. Therefore, the demonstration that ZIKV 
infection in human macrophages follows the same trend of production of type I IFN and 
pro-inflammatory cytokines as seen in Hofbauer cells, leads to the conclusion that 
macrophages are capable of mounting a strong antiviral defense to ZIKV.  
 
Since testicular macrophages are in close proximity to the seminiferous tubules, we 
hypothesize that they contribute to the testicular infection of ZIKV in two ways. First, they 
could serve as a primary source for ZIKV dissemination to other resident testicular cells 
including SC and Leydig cells during the viremic phase, and secondly, inflammatory 
mediators released from infected macrophages may alter the testicular immune 
environment, thus favoring loss of TJP and leakiness of the SCB as shown in Fig. 8. Our 
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data demonstrating loss of ZO-1 and decreased barrier integrity following treatment with 
supernatant from infected macrophages support this notion that SC are susceptible to 
changes in the local inflammatory mediators. In an in vivo scenario, a direct consequence 
of ZIKV infection of both SC and testicular macrophages could be an altered local 
inflammation status leading to an enhanced infiltration of macrophages and adaptive 
immune cells into the lumen, thereby damaging the developing spermatocytes. However, 
the role of other cell types, e.g., Leydig cells and peritubular cells, in modulating the local 
inflammatory milieu and acting as a reservoir of ZIKV cannot be ruled out.  
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Fig. 8.  Putative interactions between ZIKV and the SCB. During viremic stage, ZIKV 
reaches the peritubular compartment of the testes via peripheral immune cells and infects 
SC. Infection of SC induces robust innate immune response with no cytopathic effects. The 
virus replication does not affect levels of TJP or SCB integrity, but is efficiently released on 
the adluminal side of seminiferous tubules, where elongated spermatids are present. ZIKV 
infection also induces expression of cell-adhesion molecules like VCAM-1 and ICAM-1 that 
facilitate adhesion of naïve immune cells to SC and compromise SCB permeability. ZIKV 
infection in macrophages results in the production of inflammatory cytokines and 
chemokines that can degrade TJP ZO-1 and directly affect the integrity of the SCB. Further, 
anti-viral NITD008 is able to completely block ZIKV infection in SC. A direct consequence 
of ZIKV infection in these cell types may include establishment of persistence in the 
seminiferous tubules and infiltration of macrophages in the lumen.  
 
 
In vitro SCB models comprised of human and mouse SC have been used to study 
mechanisms of SC function in spermatogenesis and effects of environmental toxins on 
barrier integrity leading to male infertility [116, 117]. However, this study for the first time 
uses an in vitro model of SCB to characterize virus transmigration kinetics and to 
understand interactions of infected peritubular leukocytes with SC. Further, our data 
demonstrating the dose-dependent effect of a well-tested anti-flavivirus compound, 
NITD008, in blocking ZIKV replication in SC is encouraging and warrants future in vivo 
studies to test whether this drug can cross the SCB and clear testicular ZIKV infection. A 
recent study has reported inhibition of ZIKV in Vero cells and in a mouse model by 
NITD008, however this study did not examine ability of this drug to clear testicular infections 
[84]. Our in vitro model of SCB can not only be used as a tool to characterize testicular 
infections of other viruses including Ebola virus, but will also allow rapid testing of new 
antiviral drugs to cross the SCB and mitigate infection in the seminiferous tubules. In 
summary, this study provides the much-needed evidence that ZIKV infection of human SC 
is one of the mechanisms by which this virus might enter the intratubular compartment of 
the seminiferous tubules to establish persistent infection in testes. The data further provide 
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insights that disruption of the SCB may be one of the mechanisms by which ZIKV-infected 
macrophages cause testicular damage and lays a platform for future studies on how ZIKV 
infection may affect the interaction between SC and other testes resident cells including 
Leydig cells. Once the specific pathways and cell types involved in the dissemination of 
virus to developing spermatids are known, the system can be manipulated 
pharmacologically to test innovative approaches for the treatment of testicular ZIKV 
infection in humans. 
 
Materials and methods: 
Ethics statement: Human monocytes and PBMCs were isolated from fresh blood obtained 
from healthy donors under a protocol (CHS#24091) approved by the University of Hawaii 
Institutional Review Board for Human Subjects. All subjects were adult and gave informed 
written consent. 
 
Cells and virus: Low-passage primary human Sertoli cells (HSEC) purchased from Lonza 
(MM-HSE-2305) were propagated in DMEM and F-12 media in the ratio of 1:1 with HEPES, 
L-Gln, 100 units/mL Pen-Strep and 5% untreated FBS according to manufactures protocol. 
Early-passage HBMVEC purchased from Cell Systems Cooperation (CSC 2M1) were 
grown as previously described [131]. All experiments of primary HSEC and HBMVEC cells 
were conducted using passage 6-9 at 80-90% confluency. ZIKV strain PRVABC59 
(Human/2015/Puerto Rico) acquired from American Type Culture Collection (ATCC) was 
propagated once in Vero E6 cells (ATCC). DENV-2 New Guinea C strain and WNV NY99 
strains were also propagated once in Vero cells. Stock virus was used for infection at MOI 
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1 or 5 for 1 hr at 37oC followed by 2 washes and replaced with fresh media. UV-inactivated 
ZIKV (UV-ZIKV) was generated by exposing the virus stock to UV radiation for 10 min 
(Stratagene, Stratalinker 2400) as described previously for WNV [131]. In some 
experiments, HSEC were infected with DENV2 (New Guinea C strain) or ZIKV in the 
presence of NITD008, an anti-flavivirus compound at different concentrations prepared as 
described previously [84]. 
 
PBMC isolation and monocyte separation: The PBMCs were isolated from 20-40 mL of 
anti-coagulated blood of healthy donors using Ficoll density gradient centrifugation and 
monocytes were differentiated into macrophages by culturing adhered monocytes in 24-
well plates in X-vivo media for 6 days. For some experiments, monocytes were separated 
using the EasyStep Negative Selection Human Monocyte Enrichment Kit (StemCell 
Technologies) as described previously [122] and used immediately for incubation with 
HSEC monolayers or inserts. By this method, the purity of monocytes was 99% and the 
viability was 97-99%.  
 
ZIKV quantitation using plaque assay and qRT-PCR: ZIKV titers in the cell culture 
supernatants were analyzed by a standard plaque assay using Vero cells [131]. Intracellular 
virus replication was measured by qRT-PCR using primer and probe specific for ZIKV Env 
region as described previously [132]. The data are expressed as ZIKV PFU per mL 
supernatant or PFU equivalents per μg RNA. 
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Analysis of host response: Total RNA extracted from HSEC and macrophages collected 
at different time points after infection was used to measure changes in the transcripts of 
multiple innate immune genes, TJP and CAM by qRT-PCR using specific primers as 
described previously [122, 131]. The housekeeping gene GAPDH was utilized to normalize 
each gene and fold change as compared to un-infected control was calculated as described 
previously [131]. The protein levels of TJP (ZO-1, claudin, occludin and JAM-A) and CAM 
(VCAM-1 and E-selectin) in HSEC were also determined by Western blotting using specific 
antibodies as described previously [131]. For further confirmation by immunostaining, 
mock- and ZIKV-infected HSEC grown on coverslips were fixed in 4% paraformaldehyde 
(PFA) at 48 hrs after infection and immunostained using biotinylated monoclonal mouse or 
anti-ZO-1 (1:100 dilution) followed by streptavidin 488 conjugated anti-mouse secondary 
antibodies and examined using an Axiocam MR camera mounted on a Zeiss Axiovert 200 
microscope as described previously [131]. Multiple cytokines and chemokines including 
IFN-α secreted in the cell culture supernatant from ZIKV-infected HSEC and human 
macrophages were quantitated by Luminex assay using a Milliplex Map Human 
Cytokine/Chemokine kit (Millipore) and read on a Luminex200 LiquiChip analyzer as 
described previously [133].  
 
Development of Sertoli-cell barrier (SCB) model, ZIKV infection and permeability 
assay: An in vitro SCB model was constructed using CorningÒ BiocoatÔ Human Fibronectin 
PET (polyethylene terephthalate) inserts with a 3.0 µm pore size and 0.33 cm2 membrane 
surface area in a 24-well plate. Briefly, after rehydrating the inserts following manufacturer’s 
protocol, they were seeded with 6 x 104 HSEC or HBMVEC on the upper surface and 
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incubated with 500 µl media in both upper and lower chambers at 37°C, 5% CO2, and 100% 
humidity. The integrity of the in-vitro SCB model was first determined four days after 
seeding, then subsequently every 2-3 days by measuring Trans-Endothelial Electrical 
Resistance (TEER) using an Epithelial Volt/Ohm Meter (EVOMX, World Precision 
Instrument) and Endohm-6 chamber and expressed as (W/cm2) as described previously 
[131]. The media was replaced from both the upper and lower chambers during each TEER 
measurement. Ten days after seeding when the TEER readings crossed 110 W/cm2, the 
inserts were infected with ZIKV or UV-ZIKV for 1 hr following which the inserts were gently 
washed twice with HSEC media to remove unbound virus. TEER was measured at 24, 48, 
and 72 hrs after infection and the upper and lower chamber supernatants (UCS and LCS, 
respectively) were collected for quantitative virus assays. For some experiments the upper 
chambers of ZIKV-infected SCB inserts were incubated with either 2.5 x 104 naïve PBMCs 
and monocytes or 350ul of supernatant from ZIKV-infected human macrophages collected 
at 48 hrs after infection mixed with 150 µl of HSEC media and TEER was measured after 
2 hrs of treatment. The integrity of inserts following PBMC/monocytes transmigration and 
supernatant treatment was also assessed using the FITC-dextran (4-kDA MW, Sigma) 
transmigration assay as described in our previous studies [131]. The transmigration of 
FITC-dextran across the inserts was calculated as percentage of the total amount added in 
the upper chamber.  
 
Adhesion assay: Confluent monolayers of HSEC cells grown on coverslips in 24 well 
plates were infected with ZIKV at MOI 1 and 5. At day 3 of infection, 2.5 x 104 naïve 
monocytes or PBMCs were added on the coverslips and co-cultured with HSEC for 2 hrs 
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at 37°C. At the end of the incubation period, the non-adherent monocytes or PBMCs were 
removed by washing four times to remove loosely attached cells. The co-cultured 
monolayers were fixed in 4% PFA for 10 minutes and were stained with FITC conjugated 
anti-CD45 (a surface leukocyte marker) diluted 1:100 and DAPI for nuclear staining as 
described previously [122].  Controls included uninfected HSEC cells co-cultured with 
leukocytes. The number of leukocytes bound to the monolayers was determined by 
counting the number of adherent CD45+ cells in two central and two peripheral randomly 
selected fields of at least 3 coverslips from two independent infections.  
 
Cell viability assay: 
 
Cell viability was measured in HSEC 72 hours after infection with ZIKV, DENV, and WNV 
using the Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay (Catalog # 
G3582).  Briefly 20µL of One Solution Reagent was added to both mock- and viral- 
infected wells containing 100µL of HSEC media. Wells were incubated for 2 hours before 
reading the absorbance at 490nm on a Victor X Plate Reader.  
 
Statistical analysis: ZIKV virus titer, mRNA fold-change and Luminex data are reported 
as mean ± SEM of at least triplicates from two independent experiments. Unpaired Student 
t-test was used to compare the values of permeability and transmigration assays using 
GraphPad Prism 5.0 0 (GraphPad software, San Diego, CA). p<0.05 was considered as 
statistically significant for all analyses. 
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Supplemental figures: 
 
 
 
 
Supplemental Fig. 1: Infection with ZIKV, DENV, and WNV does not result in CPE 
or cell death in HSEC Cell viability was measured in HSEC 72 hours after infection with 
ZIKV, DENV, and WNV at MOI 1 using the CellTiter 96 AQueous One Solution Cell 
Proliferation Assay. 
 
 
 
Supplemental Fig. 2: ZIKV, DENV, and WNV cause productive infection in HSEC 
HSEC were infected with ZIKV, DENV, and WNV at MOIs 0.01, 0.1, and 1.0. Virus titers 
were quantified by plaque assay using Vero cells and expressed as PFU/mL supernatant. 
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Chapter 4 
Summary and future directions 
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Summary: 
 
Re-emerging ZIKV is a major health concern as it continues to expand to new regions of 
the world with increased cases and disease severity. Contributing to this current outbreak 
are unique features of the virus such as its ability to infect a wide range of tissues/organs, 
invade immune privileged organs such as the brain, eye, and testes, and to be transmitted 
both sexually and in utero. Shockingly, these findings have never been described with old 
world ZIKV and it is not entirely clear whether these disease characteristics were 
undiagnosed in previous outbreaks or are because of mutations in the viral genome 
and/or ADE like phenomenon as suggested by few experts in the field [24]. We believe 
that as sexual transmission increases the risk of infection, prolongs current outbreaks, 
and represents a serious threat in women of reproductive age, it is of the utmost 
importance to study the cellular and molecular mechanisms responsible for both 
prevention and disease management. 
 
When we initiated this study, case reports on the newly documented phenomenon of ZIKV 
sexual transmission and virus presence in human seminal fluid were the only available 
literature [35, 36, 114]. Later, few in vivo NHP and mouse models provided the first 
evidence that ZIKV was able to target the testes in the male reproductive tract and 
provided the strongest scientific premise to take up this study [2-5]. Based on the immune 
privileged nature of the testes and association of ZIKV with the cellular portion of seminal 
fluid and sperm, we formulated the hypothesis that ZIKV will infect human Sertoli cells 
and cross the Sertoli-cell barrier to establish a persistent infection in the seminiferous 
tubules. Our overall objective, therefore, was to characterize ZIKV replication kinetics and 
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immune responses in primary human Sertoli cells (HSEC) and develop an in vitro SCB 
model to understand mechanisms of ZIKV transmigration across the SCB. 
 
For specific aim 1, we utilized HSEC to compare infection of the recently isolated Puerto 
Rican strain of ZIKV (PRVABC59) with related flaviruses such as DENV-2 (New Guinea 
C strain) and WNV (NY99) at three different MOIs (0.01, 0.1, and 1.0). We found that 
HSEC were highly susceptible to ZIKV with viral titers peaking at 48 and 72 hours after 
infection suggesting that they may be one of the targets of the virus in the testes. HSEC 
also supported robust infection of WNV and this finding was at first surprising since WNV 
has so far not been labeled as a sexually transmitted pathogen. However, it is well 
established that WNV has far more wide range of tissue tropism as compared to DENV, 
which may explain our data. Also, due to the fact that WNV requires birds as an amplifying 
host in nature to achieve high virus titers to induce viremia and human disease, we 
speculate that even if in rare cases WNV infects testes, it may not be able to sexually 
transmit as the virus may not achieve titers high enough in the semen to induce viremia 
in their partners. Another interesting finding was that DENV produced much lower viral 
progeny than ZIKV and WNV thus indicating that flaviviruses exhibit different infection 
kinetics in SC.  
 
The first aim also sought to characterize innate immune responses and barrier integrity 
markers in HSEC and MDM following ZIKV infection. Our results support our hypothesis 
and demonstrate robust antiviral and inflammatory responses in both HSEC and MDM. 
These data also support previous studies that indicated that SC could participate in 
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immune responses to other testes-tropic viruses [106]. Another novel finding of this aim 
is that direct infection of ZIKV does not affect the expression of TJP, which are critical for 
maintain the SCB integrity.  As the data on the replication kinetics of ZIKV in MDM is 
relatively limited, our results from human MDM are also important in understanding 
peripheral immunity to the ZIKV. Finally, our data demonstrating complete blockage of 
ZIKV infection by NITD008 in HSEC highlights the potential for in vivo testing of this drug 
to treat testicular infection. 
The objective of the second aim was to test the hypothesis that ZIKV infection of HSEC 
and macrophages lead to disruption of the in vitro SCB model. This model had only been 
used to study the mechanisms of SC function in spermatogenesis and the effects of 
environmental toxins on barrier integrity, therefore our study was the first to utilize the model 
to examine virus transmigration kinetics.  We found that ZIKV was able to successfully 
transmigrate across the in vitro SCB barrier to the adluminal side of the membrane. 
Interestingly, infection also increased the ability of peripheral immune cells to adhere to the 
HSEC monolayer, which correlated with an increase in barrier permeability. Lastly, 
inflammatory mediators secreted from ZIKV infected macrophages were also found to 
compromise the barrier integrity and suggest that inflammatory mediators released from 
ZIKV-infected cells in the peritubular compartment possess the potential of disrupting the 
SCB. Our results collectively supported the overall hypothesis of this aim and provided 
strong support for the use of this in vitro SCB model to delineate interaction between 
different testicular cells. 
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Overall, our data suggest that infection of SC may be one of the crucial steps by which 
ZIKV gains access to immune privileged seminiferous tubules. We propose that SC may 
serve as a reservoir for infection of other resident testicular cells including spermatogonia 
and developing spermatozoa. Furthermore, since testicular macrophages are in close 
proximity to the seminiferous tubules, we strongly believe that they could serve as a primary 
source of ZIKV dissemination to resident testicular cells and release inflammatory 
mediators that may alter and affect the structure of the SCB. Although this study provides 
useful insight into the mechanisms of ZIKV pathogenesis in the human testes and serves 
as a proof of concept, additional follow up studies both in vitro and in vivo will be needed to 
further delineate the role of other cell types in ZIKV testicular infection. 
	
	
Future directions: 
	
The data obtained from this study opens up many new avenues of investigation into the 
mechanisms of testicular ZIKV infection. Since the specific cell receptor/receptors that 
ZIKV utilizes to enter host cells is currently under intense investigation, the most 
interesting future direction would be to identify the cell receptors involved in ZIKV entry 
into Sertoli cells. Previous studies have demonstrated that certain TAM proteins enhance 
infection of DENV, WNV, and YF in astrocytes and epithelial cells [134]. TAM proteins 
specifically belong to a family of receptor tyrosine kinases (RTKs), which includes Tyro3, 
Axl, and Mertk. These RTKs have two common ligands, namely, growth arrest specific 
gene 6 (Gas6) and protein S (ProS) (Figure 1) and the TAM-Gas6/ProS complex plays 
critical roles in both the phagocytic removal of apoptotic cells and regulating immune 
responses [105, 134].  
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Figure 1: Hypothetical model for flavivirus recognition by TAM receptors [134] 
Recent studies have shown that TAM receptors, Axl in particular, are involved in ZIKV 
entry in skin fibroblasts, glial cells, and neural stem cells [27, 135, 136] [137]. However, it 
appears that there is some cell-specificity in dependency of Axl as an entry receptor as 
Wells et al. demonstrated that blocking Axl receptor did not limit ZIKV entry and infection 
in human neural progenitor cells and cerebral organoids [138]. This suggests that ZIKV 
may use more than one receptor to enter and that may define higher replication of the 
virus in one cell type versus another.   
Interestingly, the testes are one of the few organs that expresses high basal levels of 
TAM receptors. SC are specifically known to highly express Axl on their surface  that is 
thought to help maintain homeostasis [105]. Since our data suggests that HSEC are one 
of the targets of ZIKV in human testes, the next logical extension would be to determine 
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if Axl plays an essential role in mediating ZIKV entry into these cells. Furthermore, I would 
like to investigate whether ZIKV infection in HSEC increases the secretion of Gas6, Axl 
ligand. If the Axl-Gas6 complex can bind to ZIKV and facilitate its entry, it could be taken 
advantage for the development of therapeutic strategies to prevent testicular infection.  
 
Although our data indicated that SC induced robust innate immunity to ZIKV, the specific 
PRRs associated with detection or ZIKV and downstream pathways of innate immunity 
are yet to be defined. Therefore, another important follow up direction would be to 
investigate what are the upstream PPR pathways activated by ZIKV in SC. This could be 
accomplished by utilizing high throughput next generation RNA-sequencing (RNA-seq) 
technology, which would allow comprehensive analysis of global host response to ZIKV 
and help us identify if PRRs such as TLR3 or RIG-I and downstream pathways are 
activated by ZIKV. Additionally, RNA-seq will also potentially identify other important 
pathways/networks involved in SC-germ cell signaling as well as apoptotic and cell cycle 
arrest pathways. Activation of these pathways may further suggest that ZIKV can affect 
the function of the seminiferous epithelium and spermatogenesis. Collectively, this 
information will provide mechanistic clues to ZIKV testicular infection and lay platform for 
future studies to assess function of key host pathways in ZIKV persistence in the testes.  
 
Finally, while this study supports the strength of SCB model in understanding human 
testicular infection of ZIKV, it also opens up opportunities to test other in vitro models that 
more closely represent human testes. A major limitation of the monolayer cell cultures is 
that they do not allow assessment of the interaction of multiple testicular cells, specifically 
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between SC and developing spermatozoa. Given that the existing immunocompromised 
animal models also have their limitations regarding applicability to human disease, there 
is a need to develop novel tools to study human testicular virus infections. One available 
model is the three dimensional (3D) human testicular organoid (HTO) culture system, 
which was recently developed for drug-screening and human testicular function [139]. 
Specifically, this system is composed of spermatogonial stem cells (SSC), Sertoli, Leydig, 
and peritubular cells isolated from human testicular tissue, which grow together to form 
organoids and closely mimics the human testicular microenvironment [139]. Furthermore, 
in vitro studies have demonstrated that this model produces testosterone continuously, 
maintains more than 85% viability throughout long-term culture of 23 days, and provides 
evidence of differentiation of SSC into meiotic spermatogonia [139]. This 3D HTO culture 
system could be utilized as a novel tool to address specific questions that cannot be 
assessed in a monolayer culture system. Because the 3D HTO culture system allows 
differentiation of germ cells, it could be used to evaluate the effect of ZIKV infection on 
different stages of spermatogenesis.  
 
Collectively, the information acquired from our study and the proposed future experiments 
may provide mechanistic insight into the testicular pathology and persistence of ZIKV and 
may identify therapeutic targets to combat the virus. In conclusion, active research is 
warranted in delineating pathogenesis of ZIKV in human testes as it will ultimately help 
inform public health guidelines, impact the development of novel therapeutic strategies, 
and the ultimate goal of decreasing the disease burden and ZIKV-associated birth defects 
worldwide. 
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